Research Publications 2017

Aibibula W, Cox J, Hamelin AM, McLinden T, Klein MB, Brassard P. Association between food insecurity and HIV viral suppression: a systematic review and meta-analysis. AIDS Behav. 2017 Mar;21(3):754-65.

Antoniou T, Szadkowski L, Walmsley SL, Cooper C, Burchell AN, Bayoumi AM, Montaner JSG, Loutfy MR, Klein MB, Machouf N, Tsoukas C, Wong A, Hogg RS, Raboud JM; Canadian Observational Cohort (CANOC) Collaboration. Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients. BMC Infect Dis. 2017 Apr;17(1):266.

Balfour L, Wiebe SA, Cameron WD, Sandre D, Pipe A, Cooper C, Angel J, Garber G, Holly C, Dalgleish TL, Tasca GA, MacPherson PA. An HIV-tailored quit-smoking counselling pilot intervention targeting depressive symptoms plus Nicotine Replacement Therapy. AIDS Care. 2017 Jan;29(1):24-31.

Balogun KA, Lenis MG, Papp E, Loutfy MR, Yudin MH, MacGillivray J, Walmsley SL, Silverman M, Serghides L. Elevated levels of estradiol in HIV-positive pregnant women on protease inhibitor-based regimens. Clin Infect Dis. 2017 Aug 24 [epub ahead of print].

Benoit AC, Younger J, Beaver K, Jackson R, Loutfy MR, Masching R, Nobis T, Nowgesic E, O’Brien-Teengs D, Whitebird W, Zoccole A, Hull MW, Jaworsky D, Benson E, Rachlis A, Rourke SB, Burchell AN, Cooper C, Hogg RS, Klein MB, Machouf N, Montaner JSG, Tsoukas C, Raboud JM. Increased mortality among Indigenous persons in a multisite cohort of people living with HIV in Canada. Can J Public Health. 2017 Jun;108(2):e169-75.

Card KG, Lachowsky NJ, Cui Z, Shurgold S, Armstrong HL, Rich AJ, Forrest JI, Gislason M, Moore DM, Roth EA, Hogg RS. An event-level analysis of the interpersonal factors associated with condomless anal sex among gay, bisexual, and other men who have sex with men (MSM) with online-met partners. AIDS Educ Prev. 2017 Apr;29(2):154-74.

Card KG, Armstrong HL, Lachowsky NJ, Cui Z, Sereda P, Carter MA, Montaner JSG, Hogg RS, Roth EA, Moore DM. Belief in treatment as prevention and its relationship to HIV status and behavioral risk. JAIDS. 2017 Oct 4 [epub ahead of print].

Carter A, Loutfy MR, de Pokomandy A, Colley G, Zhang W, Sereda P, O’Brien N, Proulx-Boucher K, Nicholson VJ, Beaver K, Kaida A; on Behalf of the CHIWOS Research Team. Health-Related Quality-Of-Life and Receipt of Women-Centred HIV Care among Women Living with HIV in Canada. Women Health. 2017 Apr;163(3):265.

Carter A, Loutfy MR, de Pokomandy A, Colley G, Zhang W, Sereda P, O’Brien N, Proulx-Boucher K, Nicholson VJ, Beaver K, Kaida A; on behalf of the CHIWOS Research Team. Health-Related Quality-Of-Life and Receipt of Women-Centred HIV Care among Women Living with HIV in Canada. Women Health. 2017 Apr;163(3):265.

Carter A, de Pokomandy A, Loutfy MR, Ding E, Sereda P, Webster K, Nicholson VJ, Beaver K, Hogg RS, Kaida A; on behalf of the CHIWOS Research Team. Validating a self-report measure of HIV viral suppression: an analysis of linked questionnaire and clinical data from the Canadian HIV Women’s Sexual and Reproductive Health Cohort Study. BMC Res Notes. 207;10(1):138.

Carter A, Roth EA, Ding E, Milloy MJ, Kestler M, Jabbari S, Webster K, de Pokomandy A, Loutfy MR, Kaida A; on behalf of the CHIWOS Research Team. Substance use, violence, and antiretroviral adherence: A latent class analysis of women living with HIV in Canada. AIDS Behav. 2017 Jul 21 [epub ahead of print].

Delaugerre C, Antoni G, Mahjoub N, Pialoux G, Cua E, Pasquet A, Hall N, Tremblay CL, Cotte L, Capitant C, Chaix ML, Meyer L, Molina JM; IPERGAY study group. Assessment of HIV screening tests for pre-exposure prophylaxis programs. J Infect Dis. 2017 Jun 27 [epub ahead of print].

Durand M, Chartrand-Lefebvre C, Baril JG, Trottier S, Trottier B, Harris M, Walmsley SL, Conway B, Wong A, Routy JP, Kovacs C, MacPherson PA, Monteith KM, Mansour S, Thanassoulis G, Abrahamowicz M, Zhu Z, Tsoukas C, Ancuta P, Bernard N, Tremblay CL; for the Canadian HIV and Aging Cohort Study. The Canadian HIV and aging cohort study – Determinants of increased risk of cardiovascular diseases in HIV-infected individuals: Rationale and study protocol. BMC Infect Dis. 2017 Sep 11;17(1):611.

Durand-Zaleski I, Mutuon P, Charreau I, Tremblay CL, Rojas D, Pialoux G, Chidiac C, Capitant C, Spire B, Cotte L, Chas J, Meyer L. Costs and benefits of on-demand HIV pre-exposure prophylaxis in men who have sex with men analysis of the ANRS IPERGAY study with a one-year follow-up. AIDS. 2017 Oct 12 [epub ahead of print].

Fernández-Cruz AL, Fellows LK. The electrophysiology of neuroHIV: A systematic review of EEG and MEG studies in people with HIV infection since the advent of highly-active antiretroviral therapy. Clin Neurophysiol. 2017 Jun;128(6):965-76.

Gosselin A, Wiche Salinas TR, Planas D, Wacleche VS, Zhang Y, Fromentin R, Chomont N, Cohen ÉA, Shacklett B, Mehraj V, Ghali MP, Routy JP, Ancuta P. HIV persists in CCR6+CD4+ T cells from colon and blood during antiretroviral therapy. AIDS. 2017 Jan;31(1):35-48.

Jackson E, Zhang CX, Kiani Z, Lisovsky I, Tallon B, Del Corpo A, Gilbert L, Bruneau J, Thomas R, Côté P, Trottier B, Leblanc R, Rouleau D, Tremblay CL, Tsoukas CM, Routy JP, Ni X, Mabanga T, Bernard NF; Montreal Primary Infection Study Group. HIV exposed seronegative (HESN) compared to HIV infected individuals have higher frequencies of telomeric Killer Immunoglobulin-like Receptor (KIR) B motifs; Contribution of KIR B motif encoded genes to NK cell responsiveness. PLoS ONE. 2017 Sep 22;12(9):e0185160.

Joyce VR, Sun H, Barnett PG, Bansback N, Griffin SC, Bayoumi AM, Anis AH, Sculpher M, Cameron W, Brown ST, Holodniy M, Owens DK. Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV. MDM Policy & Practice. 2017 Jul 3 [epub ahead of print].

Klassen BJ, Lachowsky NJ, Lin SY. Gay men’s understanding and education of new HIV prevention technologies in Vancouver, Canada. Qual Health Res. 2017;3(2):1-17.

van der Kop ML, Muhula S, Ekström AM, Jongbloed K, Smillie K, Abunah B, Kinagwi K, Kyomuhangi LB, Gelmon L, Ojakaa DI, Lester RT, Awiti PO. Participation in a mobile health intervention trial to improve retention in HIV care: does gender matter? J Telemed Telecare. 2017 Feb;23(2):314-20.

Kronfli N, Lacombe-Duncan A, Wang Y, de Pokomandy A, Kaida A, Logie C, Conway T, Kennedy VL, Burchell A, Tharao W, Pick N, Kestler M, Sereda P, Loutfy MR; On Behalf of the CHIWOS Research Team. Access and engagement in HIV care among a national cohort of women living with HIV in Canada. AIDS Care. 2017 Jun 13 [epub ahead of print].

Kronfli N, Lacombe-Duncan A, Wang L, de Pokomandy A, Kaida A, Logie CH, Conway T, Kennedy VL, Burchell AN, Tharao W, Pick N, Kestler M, Sereda P, Loutfy MR; On Behalf of the CHIWOS Research Team. Understanding the correlates of attrition associated with antiretroviral use and viral suppression among women living with HIV in Canada. AIDS Patient Care STDS. 2017 Oct 1;31(10):428-37.

Lachowsky NJ, Dulai JJS, Cui Z, Sereda P, Rich A, Patterson TL, Corneil TT, Montaner JSG, Roth EA, Hogg RS, Moore DM. Lifetime doctor-diagnosed mental health conditions and current substance use among gay and bisexual men living in Vancouver, Canada. Subst Use Misuse. 2017 May;52(6):785-97.

Logie CH, Kaida A, de Pokomandy A, O’Brien N, O’Campo P, MacGillivray J, Ahmed U, Arora N, Wang L, Jabbari S, Kennedy L, Carter A, Proulx-Boucher K, Conway T, Sereda P, Loutfy MR; Team OBOTCR. Prevalence and correlates of forced sex as a self-reported mode of HIV acquisition among a cohort of women living with HIV in Canada. J Interpers Violence. 2017 Jul 12 [epub ahead of print].

Logie CH, Lacombe-Duncan A, Wang Y, Kaida A, de Pokomandy A, Webster K, Conway T, Loutfy MR. Sexual orientation differences in health and wellbeing among women living with HIV in Canada: Findings from a national cohort study. AIDS Behav. 2017 Apr 25 [epub ahead of print].

Loutfy MR, Margolese S, Money DM, Gysler M, Hamilton S, Yudin MH. Lignes directrices canadiennes en matière de planification de la grossesse en présence du VIH. J Obstet Gynaecol Can. 2016 Dec;38(12S):S59-78. 2017 Jan 4 [epub ahead of print].

Loutfy MR, de Pokomandy A, Kennedy VL, Carter A, O’Brien N, Proulx-Boucher K, Ding E, Lewis J, Nicholson VJ, Beaver K, Greene S, Tharao W, Benoit A, Dubuc D, Thomas-Pavanel J, Sereda P, Jabbari S, Shurgold JH, Colley G, Hogg RS, Kaida A; CHIWOS Research Team. Cohort profile: The Canadian HIV Women’s Sexual and Reproductive Health Cohort Study (CHIWOS). PLoS ONE. 2017 Sep 28;12(9):e0184708.

MacKenzie LJ, Hull MW, Samji H, Lima VD, Yip B, Zhang W, Lourenço L, Colley G, Hogg RS, Montaner JSG. Is there a rural/urban gap in the quality of HIV care for treatment-naïve HIV-positive individuals initiating antiretroviral therapy in British Columbia? AIDS Care. 2017 May;4(3):1-9.

Maponga TG, Matsha RM, Morin S, Scheibe A, Swan T, Andrieux-Meyer I, Spearman CW, Klein MB, Rockstroh JK. Highlights from the 3rd international HIV/viral hepatitis Co-infection meeting—HIV/viral hepatitis: improving diagnosis, antiviral therapy and access. Hepatology, Medicine and Policy. 2017;2(1):8.

Martel-Laferrière V, Nitulescu R, Cox J, Cooper C, Tyndall M, Rouleau D, Walmsley S, Wong L, Klein MB; Canadian Co-infection Cohort Study Investigators. Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study. BMC Infect Dis. 2017 Jan 17;17(1):80.

Mayo NE, Aburub A, Brouillette MJ, Kuspinar A, Moriello C, Rodriguez AM, Scott S. In support of an individualized approach to assessing quality of life: comparison between Patient Generated Index and standardized measures across four health conditions. Qual Life Res. 2017;26(3):601-9.

McLinden T, Moodie EEM, Hamelin AM, Harper S, Walmsley SL, Paradis G, Aibibula W, Klein MB, Cox J. Injection drug use, unemployment, and severe food insecurity among HIV-HCV co-infected individuals: A mediation analysis. AIDS Behav. 2017 Jul 19 [epub ahead of print].

Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay CL, Rojas Castro D, Cua E, Pasquet A, Bernaud C, Pintado C, Delaugerre C, Sagaon-Teyssier L, Mestre SL, Chidiac C, Pialoux G, Ponscarme D, Fonsart J, Thompson D, Wainberg MA, Doré V, Meyer L; ANRS IPERGAY Study Group. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: An observational cohort study. Lancet HIV. 2017 Sep;4(9)e402-10.

Moore DM, Cui Z, Lachowsky NJ, Rich AJ, Roth EA, Raymond HF, Sereda P, Montaner J, Wong J, Armstrong HL, Hall D, Hogg RS. Increasing HIV treatment optimism but no changes in HIV risk behaviour among men who have sex with men (MSM) in Vancouver, Canada. JAIDS. 2017 Sep 6 epub ahead of print.

Moqueet N, Kanagaratham C, Gill MJ, Hull MW, Walmsley SL, Radzioch D, Saeed S, Platt RW, Klein MB; Canadian Co-infection Cohort Study (CTN 222). A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. PLoS ONE. 2017 May;12(5):e0176282.

O’Brien N, Greene S, Carter A, Lewis J, Nicholson VJ, Kwaramba G, Ménard B, Kaufman E, Ennabil N, Andersson N, Loutfy MR, de Pokomandy A, Kaida A; for the CHIWOS Research Team. Envisioning women-centered HIV care: Perspectives from women living with HIV in Canada. Womens Health Issues. 2017 Sep 5 [epub ahead of print].

Pai NP, Smallwood M, Gulati D, Lapczak N, Musten A, Gaydos C, Johnston C, Steben M, Wong T, Engel N, Kim J. What do key stakeholders think about HIV self-testing in Canada? Results from a cross-sectional survey. AIDS Behav. 2017;10(4):e1001414–10.

Patel AR, Kessler J, Braithwaite RS, Nucifora KA, Thirumurthy H, Zhou Q, Lester RT, Marra CA. Economic evaluation of mobile phone text message interventions to improve adherence to HIV therapy in Kenya. Medicine. 2017 Feb;96(7):e6078.

Patel AR, Lester RT, Marra CA, van der Kop ML, Ritvo P, Engel L, Karanja S, Lynd LD. The validity of the SF-12 and SF-6D instruments in people living with HIV/AIDS in Kenya. Health Qual Life Outcomes. 2017 Jul 17;15(1):143.

Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell AN, Cooper C, Hill T, Hull MW, Klein MB, Loutfy M, Martin F, Machouf N, Montaner JSG, Nelson M, Raboud JM, Rourke SB, Tsoukas C, Hogg RS, Sabin C; Canadian Observational Cohort (CANOC), UK Collaborative HIV Cohort (UK CHIC) Collaboration. A tale of two countries: All-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. HIV Med. 2017 Apr 24 [epub ahead of print].

Planas D, Zhang Y, Monteiro P, Goulet J-P, Gosselin A, Grandvaux N, Hope TJ, Fassati A, Routy JP, Ancuta P. HIV-1 selectively targets gut-homing CCR6+CD4+ T cells via mTOR-dependent mechanisms. JCI Insight. 2017 Aug 3;2(15).

de Pokomandy A, Rouleau D, Lalonde R, Beauvais C, de Castro C, Coutlée F; Human Immunodeficiency and Papilloma Virus Research Group Study Group. Argon plasma coagulation treatment of anal high-grade squamous intraepithelial lesions in men who have sex with men living with HIV: Results of a 2-year prospective pilot study. HIV Med. 2017 Aug 23 [epub ahead of print].

Ponte R, Dupuy FP, Brimo F, Mehraj V, Brassard P, Bélanger M, Yurchenko E, Bernard NF, Jenabian MA, Routy JP. Characterization of myeloid cell populations in human testes collected after sex reassignment surgery. J Reprod Immunol. 2017 Oct 14 epub ahead of print.

Rich A, Scott K, Johnston C, Blackwell E, Lachowsky N, Cui Z, Sereda P, Moore D, Hogg RS, Roth E. Sexual HIV risk among gay, bisexual, and queer transgender men: findings from interviews in Vancouver, Canada. Cult Health Sex. 2017 Apr 3 [epub ahead of print].

Rossi C, Raboud JM, Walmsley SL, Cooper C, Antoniou T, Burchell AN, Hull MW, Chia J, Hogg RS, Moodie EEM, Klein MB; Canadian Observational Cohort (CANOC) Collaboration. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis. 2017 Apr;17(1):246.

Routy JP, Mehraj V. Potential contribution of gut microbiota and systemic inflammation on HIV vaccine effectiveness and vaccine design. AIDS Res Ther. 2017 Sep 12;14(1):48.

Salters K, Loutfy MR, de Pokomandy A, Money D, Pick N, Wang L, Jabbari S, Carter A, Webster K, Conway T, Dubuc D, O’Brien N, Proulx-Boucher K, Kaida A; CHIWOS Research Team. Pregnancy incidence and intention after HIV diagnosis among women living with HIV in Canada. PLoS ONE. 2017;12(7):e0180524.

Sanford R, Fernández-Cruz AL, Scott SC, Mayo NE, Fellows LK, Ances BM, Collins DL. Regionally specific brain volumetric and cortical thickness changes in HIV-infected patients in the HAART Era. J Acquir Immune Defic Syndr. 2017 Apr;74(5):563-70.

Schafer KR, Albrecht H, Dillingham R, Hogg RS, Jaworsky D, Kasper K, Loutfy MR, MacKenzie LJ, McManus KA, Oursler KAK, Rhodes SD, Samji H, Skinner S, Sun CJ, Weissman S, Ohl ME. The continuum of HIV care in rural communities in the United States and Canada: What is known and future research directions. J Acquir Immune Defic Syndr. 2017 May;75(1):35-44.

Shariati H, Armstrong HL, Cui Z, Lachowsky NJ, Zhu J, Anand P, Roth EA, Hogg RS, Oudman G, Tonella C, Moore DM. Changes in smoking status among a longitudinal cohort of gay, bisexual, and other men who have sex with men in Vancouver, Canada. Drug Alcohol Depend. 2017 Oct 1;179:370-8.

Sharma M, Pinto AD, Kumagai AK. Teaching the social determinants of health: A path to equity or a road to nowhere? Acad Med. 2017 Apr 25 [epub ahead of print].

Slogrove AL, Bettinger JA, Janssen P. Unknown antenatal HIV-infection status has declined over time in British Columbia, Canada. J Obstet Gynaecol Can. 2017 Oct 17 epub ahead of print.

Slogrove AL, Esser MM, Cotton MF, Speert DP, Kollmann TR, Singer J, Bettinger JA. A prospective cohort study of common childhood infections in South African HIV-exposed uninfected and HIV-unexposed infants. Pediatr Infect Dis J. 2017 Feb;36(2):e38-44.

Tan DHS, Raboud JM, Szadkowski L, Szabo E, Hu H, Wong Q, Cheung AM, Walmsley SL. Novel imaging modalities for the comparison of bone microarchitecture among HIV+ patients with and without fractures: a pilot study. HIV Clin Trials. 2017 Jan;18(1):28-38.

Toupin I, Engler K, Lessard D, Wong L, Lènàrt A, Spire B, Raffi F, Lebouche B. Developing a patient-reported outcome measure for HIV care on perceived barriers to antiretroviral adherence: assessing the needs of HIV clinicians through qualitative analysis. Qual Life Res. 2017 Oct 13;17(5):785–10.

Toupin I, Engler K, Lessard D, Wong L, Lènàrt A, Raffi F, Spire B, Lebouche B. Patient profiles as organizing HIV clinicians’ ART adherence management: A qualitative analysis. AIDS Care. 2017 Aug 1 [epub ahead of print].

Wacleche V, Landay A, Routy JP, Ancuta P. The Th17 lineage: From barrier surfaces homeostasis to autoimmunity, cancer, and HIV-1 pathogenesis. Viruses. 2017 Oct 19;9(10):303.

Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, Martel-Laferriere V, Conway B, Pick N, Vachon ML, Klein MB; Canadian Co-infection Cohort Investigators. Risk factors for hepatitis C virus reinfection after sustained virologic response in patients co-infected with HIV. Clin Infect Dis. 2017 Feb 12 [epub ahead of print].

Zunza M, Cotton MF, Mbuagbaw L, Lester R, Thabane L. Interactive weekly mobile phone text messaging plus motivational interviewing in promotion of breastfeeding among women living with HIV in South Africa: Study protocol for a randomized controlled trial. Trials. 2017 July 17;18(1):331.

Research Publications 2016

Aibibula W, Cox J, Hamelin AM, Mamiya H, Klein MB, Brassard P. Food insecurity and low CD4 count among HIV-infected people: a systematic review and meta-analysis. AIDS Care. 2016 Dec;28(12):1577-85.

Antiretroviral Therapy Cohort Collaboration (ART-CC), Canadian Observational Cohort Collaboration (CANOC), The UK Collaborative HIV Cohort Study (UK CHIC), the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS. 2016 Jan 28;30(3):503–13.

Benoit AC, Cotnam J, Raboud JM, Greene S, Beaver K, Zoccole A, O’Brien-Teengs D, Balfour L, Wu W, Loutfy MR. Experiences of chronic stress and mental health concerns among urban Indigenous women. Arch Womens Ment Health. 2016 Oct;19(5):809-23.

Benoit AC, Younger J, Beaver K, Jackson R, Loutfy MR, Masching R, Nobis T, Nowgesic E, O’Brien-Teengs D, Whitebird W, Zoccole A, Hull MW, Jaworsky D, Rachlis A, Rourke S, Burchell AN, Cooper C, Hogg RS, Klein MB, Machouf N, Montaner J, Tsoukas C, Raboud JM; Building Bridges; Canadian Observational Cohort Collaboration. A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada. Antiviral therapy. 2016 Dec 7 [epub ahead of print].

Blair AH, Pearce ME, Katamba A, Malamba SS, Muyinda H, Schechter MT, Spittal PM. The Alcohol Use Disorders Identification Test (AUDIT): Exploring the factor structure and cutoff thresholds in a representative post-conflict population in Northern Uganda. Alcohol Alcohol. 2016 Dec 20 [epub ahead of print].

Brunet L, Moodie EEM, Cox J, Gill J, Cooper C, Walmsley SL, Rachlis A, Hull MW, Klein MB; Canadian Coinfection Cohort Study Investigators. Opioid use and risk of liver fibrosis in HIV/hepatitis C virus-coinfected patients in Canada. HIV Med. 2016 Jan;17(1):36–45.

Brunet L, Moodie EEM, Young J, Cox J, Hull MW, Cooper C, Walmsley SL, Martel-Laferrière V, Rachlis A, Klein MB; Canadian Co-Infection Cohort Study. Progression of liver fibrosis and modern combination antiretroviral therapy regimens in HIV-hepatitis C-coinfected persons. Clin Infect Dis. 2016 Jan 15;62(2):242–9.

Cao W, Mehraj V, Kaufmann DE, Li T, Routy JP. Elevation and persistence of CD8 T-cells in HIV infection: the Achilles heel in the ART era. J Int AIDS Soc. 2016;19(1):20697.

Cao W, Mehraj V, Trottier B, Baril JG, Leblanc R, Lebouche B, Cox J, Tremblay CL, Lu W, Singer J, Li T, Routy JP. Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization of CD8 T-cell counts. Clin Infect Dis. 2016 Jan 15;62(2):250–7.

Card KG, Lachowsky NJ, Cui Z, Carter A, Armstrong H, Shurgold S, Moore D, Hogg RS, Roth EA. A latent class analysis of seroadaptation among gay and bisexual men. Arch Sex Behav. 2016 Dec 16 [epub ahead of print].

Card KG, Lachowsky NJ, Cui Z, Sereda P, Rich A, Jollimore J, Howard T, Birch R, Carter A, Montaner J, Moore D, Hogg RS, Roth EA. Seroadaptive strategies of gay & bisexual men (GBM) with the highest quartile number of sexual partners in Vancouver, Canada. AIDS Behav. 2016 Aug 27 [epub ahead of print].

Closson K, Dietrich JJ, Nkala B, Musuku A, Cui Z, Chia, J, Gray G, Lachowsky NJ, Hogg RS, Miller CL, Kaida A. Prevalence, type, and correlates of trauma exposure among adolescent men and women in Soweto, South Africa: implications for HIV prevention. BMC Public Health. 2016 Nov;16:1191.

Closson K, Lachowsky NJ, Cui Z, Shurgold S, Sereda P, Rich A, Moore DM, Roth EA, Hogg RS. Does age matter? Sexual event-level analysis of age-disparate sexual partners among gay, bisexual and other men who have sex with men (GBM) in Vancouver, Canada. Sex Trans Infect. 2016 Nov 16 [epub ahead of print].

Costiniuk CT, Brunet L, Rollet-Kurhajec KC, Cooper CL, Walmsley SL, Gill J, Martel-Laferrière V, Klein MB. Tobacco smoking is not associated with accelerated liver disease in HIV-hepatitis C co-infection: A longitudinal cohort analysis. Open Forum Infect Dis. 2016 Mar 7;3(2):ofw050.

Dagenais-Lussier X, Aounallah M, Mehraj V, El-Far M, Tremblay CL, Sékaly R-P, Routy JP, van Grevenynghe J; Montreal Primary infection Study Group. Kynurenine reduces memory CD4 T-cell survival by interfering with IL-2 signaling early during HIV-1 infection. J Virol. 2016 Aug 12;90(17):7967-79.

Demers KR, Makedonas G, Buggert M, Eller MA, Ratcliffe SJ, Goonetilleke N, Li CK, Eller LA, Rono K, Maganga L, Nitayaphan S, Kibuuka H, Routy JP, Slifka MK, Haynes BF, McMichael AJ, Bernard NF, Robb ML, Betts MR. Temporal dynamics of CD8+ T Cell effector responses during primary HIV infection. PLoS Pathog. 2016 Aug 3;12(8):e1005805–24.

Doyle MA, Singer J, Lee T, Muir M, Cooper C. Improving treatment and liver fibrosis outcomes with metformin in HCV-HIV co- infected and HCV mono-infected patients with insulin resistance: study protocol for a randomized controlled trial. Trials. 2016 Jul 20;17(1):331.

Engler K, Lessard D, Lebouche B. A review of HIV-specific patient-reported outcome measures. The Patient. 2016 Sep 16 [epub ahead of print]. doi: 10.1007/s40271-016-0195-7.

English L, Kumbakumba E, Larson CP, Kabakyenga J, Singer J, Kissoon N, Ansermino JM, Wong H, Kiwanuka J, Wiens MO. Pediatric out-of-hospital deaths following hospital discharge: a mixed-methods study. Afr H Sci. 2016 Dec;16(4):883-91.

El-Far M, Kouassi P, Sylla M, Zhang Y, Fouda A, Fabre T, Goulet J-P, van Grevenynghe J, Lee T, Singer J, Harris M, Baril JG, Trottier B, Ancuta P, Routy JP, Bernard N, Tremblay CL; Investigators of the Canadian HIV+ Slow Progressor Cohort. Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors. Sci Rep. 2016;6:22902.

Forrest JI, Lachowsky NJ, Lal A, Cui Z, Sereda P, Raymond HF, Ogilvie GS, Roth EA, Moore D, Hogg RS. Factors associated with productive recruiting in a respondent-driven sample of men who have sex with men in Vancouver, Canada. J Urban Health. 2016 Mar 9;93(2):1–9.

Gillis J, Loutfy M, Bayoumi AM, Antoniou T, Burchell AN, Walmsley S, Cooper C, Klein MB, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Hogg R, Raboud J; CANOC Collaboration. A multi-State model examining patterns of transitioning among states of engagement in care in HIV-positive individuals initiating combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):531-9.

Gjærde LI, Shepherd L, Jablonowska E, Lazzarin A, Rougemont M, Darling K, Battegay M, Braun D, Martel-Laferrière V, Lundgren JD, Rockstroh JK, Gill J, Rauch A, Mocroft A, Klein MB, Peters L. Trends in incidences and risk factors for hepatocellular carcinoma and other liver events in HIV and hepatitis C virus co-infected individuals from 2001 to 2014: a multi-cohort study. Clin Infect Dis.  2016 Sep 15;63(6):821-9.

Graziani GM, Angel JB. HIV-1 Immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine. Expert Opin Biol Ther. 2016 July;16(7):953–66.

Hull MW, Shafran S, Wong A, Tseng A, Giguère P, Barrett L, Haider S, Conway B, Klein MB, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Can J Infect Dis Med Microbiol. 2016(6):1–34.

Jacobson JM, Routy JP, Welles S, DeBenedette M, Tcherepanova I, Angel JB, Asmuth DM, Stein DK, Baril JG, McKellar M, Margolis DM, Trottier B, Wood K, Nicolette C. Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: a randomized, double-blind, placebo-controlled clinical trial. J Acquir Immune Defic Syndr. 2016 May 1;72(1):31–8.

Jenabian MA, Mehraj V, Costiniuk CT, Vyboh K, Kema I, Rollet K, Paulino Ramirez R, Klein MB, Routy JP. Influence of hepatitis C virus sustained virological response on immunosuppressive tryptophan catabolism in ART-treated HIV/HCV coinfected patients. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):254–62.

Kesselring S, Cescon A, Colley G, Osborne C, Zhang W, Raboud JM, Hosein SR, Burchell AN, Cooper C, Klein MB, Loutfy M, Machouf N, Montaner JSG, Rachlis A, Tsoukas C, Hogg RS, Lima VD, Canadian Observational Cohort Collaboration (CANOC). Quality of initial HIV care in Canada: extension of a composite programmatic assessment tool for HIV therapy. HIV Med. 2016 Jul 6 [epub ahead of print]. doi: 10.1111/hiv.12409.

Klein MB, Rockstroh JK, Wittkop L. Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Curr Opin HIV AIDS. 2016;11(5):521-526.

van der Kop ML, Thabane L, Awiti PO, Muhula S, Kyomuhangi LB, Lester RT, Ekström AM. Advanced HIV disease at presentation to care in Nairobi, Kenya: late diagnosis or delayed linkage to care?-a cross-sectional study. BMC Infectious Diseases 2015 15:1. BioMed Central. 2016;16(1):169.

Kyle RP, Moodie EEM, Klein MB, Abrahamowicz M. Correcting for Measurement Error in Time-Varying Covariates in Marginal Structural Models. Am J Epidemiol. 2016 Aug 1;184(3):249-58.

Lachowsky NJ, Lal A, Forrest JI, Card KG, Cui Z, Sereda P, Rich A, Raymond HF, Roth EA, Moore DM, Hogg RS. Including online-recruited seeds: a respondent-driven sample of men who have sex with men. J Med Internet Res. 2016;18(3):e51–13.

Lachowsky NJ, Lin SY, Hull MW, Cui Z, Sereda P, Jollimore J, Rich A, Montaner JSG, Roth EA, Hogg RS, Moore DM. Pre-exposure prophylaxis awareness among gay and other men who have sex with men in Vancouver, British Columbia, Canada. AIDS Behav. 2016 Jul;20(7):1408-22.

Lachowsky NJ, Sorge JT, Raymond HF, Cui Z, Sereda P, Rich A, Roth EA, Hogg RS, Moore DM. Does size really matter? A sensitivity analysis of number of seeds in a respondent-driven sampling study of gay, bisexual and other men who have sex with men in Vancouver, Canada. BMC Med Res Methodol. 2016 Nov;16(1):157.

Lachowsky NJ, Tanner Z, Cui Z, Sereda P, Rich A, Jollimore J, Montaner JS, Hogg RS, Moore DM, Roth EA. An event-level analysis of condom use during anal intercourse among self-reported human immunodeficiency virus-negative gay and bisexual men in a treatment as prevention environment. Sex Transm Dis. 2016 Dec;43(12):765-770.

Lisovsky I, Isitman G, Tremblay-McLean A, Song R, DaFonnseca S, Lebouche B, Routy JP, Bruneau J, Bernard NF. The differential impact of NK cell education via KIR2DL3 and KIR3DL1 on CCL4 secretion in the context of in vitro HIV infection. Clin Exp Immunol. 2016 Dec;186(3):336-346.

Marshall AM, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Krajden M, Shoukry NH, Taylor LE, Grebely J; the Canadian Network on Hepatitis C. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJO. 2016 Oct 14;4(4):E605-14.

Mayo NE, Brouillette MJ, Fellows LK; Positive Brain Health Now Investigators. Understanding and optimizing brain health in HIV now: protocol for a longitudinal cohort study with multiple randomized controlled trials. BMC Neurol. 2016;16(1):8.

Mehraj V, Jenabian MA, Ponte R, Lebouche B, Costiniuk C, Thomas R, Baril JG, Leblanc R, Cox J, Tremblay CL, Routy JP; Primary HIV Infection the Long-Term Non-Progressors Study Groups. The plasma levels of soluble ST2 as a marker of gut mucosal damage in early HIV infection. AIDS. 2016 Jun 19;30(10):1617-27.

Mehraj V, Ponte R, Routy JP. The dynamic role of the IL-33/ST2 axis in chronic viral-infections: Alarming and adjuvanting the immune response. EBioMedicine. 2016 Jul;9:37-44.

Money DM, Moses E, Blitz S, Vandriel SM, Lipsky N, Walmsley SL, Loutfy MR, Trottier S, Smaill F, Yudin MH, Klein MB, Harris M, Cohen J, Wobeser W, Bitnun A, Lapointe N, Samson L, Brophy J, Karatzios C, Ogilvie GS, Coutlée F, Raboud JM, HPV in HIV Study Group. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. Vaccine. 2016 Sep 14;34(40):4799–806.

Moqueet N, Cooper C, Gill J, Hull MW, Platt RW, Klein MB; Canadian Co-infection Cohort. Responder interferon lambda genotypes are associated with higher risk of liver fibrosis in HIV-hepatitis C virus co-infection. J Infect Dis. 2016 Jul 1;214(1):80-6.

Milloy MJ, King A, Kerr T, Adams E, Samji H, Guillemi S, Wood E, Montaner J. Improvements in HIV treatment outcomes among indigenous and non-indigenous people who use illicit drugs in a Canadian setting. J Int AIDS Soc. 2016 Apr 18;19(1):1–8.

Otis J, McFadyen A, Haig T, Blais M, Cox J, Brenner B, Rousseau R, Émond G, Roger M, Wainberg M; Spot Study Group. Beyond condoms: risk reduction strategies among gay, bisexual, and other men who have sex with men receiving rapid HIV testing in Montreal, Canada. AIDS Behav. 2016 Dec;20(12):2812-26.

Ponte R, Mehraj V, Ghali P, Couëdel-Courteille A, Cheynier R, Routy JP. Reversing gut damage in HIV infection: using non-human primate models to instruct clinical research. EBioMedicine. 2016;4:40–9.

Rossi C, Cox J, Cooper C, Martel-Laferrière V, Walmsley SL, Gill J, Sapir-Pichhadze R, Moodie EEM, Klein MB; Canadian Co-infection Cohort Investigators. Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV co-infected patients. AIDS. 2016 Jun 1;30(9):1403-11.

Routy JP, Mehraj V, Cao W. HIV immunotherapy comes of age: implications for prevention, treatment and cure. Expert Rev Clin Immunol. 2016 Feb;12(2):91–4.

Saeed S, Strumpf EC, Walmsley SL, Rollet-Kurhajec KC, Pick N, Martel-Laferrière V, Hull MW, Gill MJ, Cox J, Cooper C, Klein MB; Canadian Co-Infection Cohort Study. How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV/HCV in the real world? Clin Infect Dis. 2016 Apr 1;62(7):919-26.

Serhir B, Hamel D, Doualla-Bell F, Routy JP, Beaulac SN, Legault M, Fauvel M, Tremblay CL, Quebec Primary HIV infection study group. Performance of Bio-Rad and limiting antigen avidity assays in detecting recent HIV infections using the Quebec Primary HIV-1 Infection Cohort. PLOS ONE. 2016;11(5):e0156023.

Siou K, Walmsley SL, Murphy KE, Raboud JM, Loutfy MR, Yudin MH, Silverman M, Ladhani NN, Serghides L. Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial. Pilot and Feasibility Studies. 2016 Aug 12;2(49):1-9.

Slogrove AL, Goetghebuer T, Cotton MF, Singer J, Bettinger JA. Pattern of infectious morbidity in HIV-exposed uninfected infants and children. Front Immunol. 2016 May 6;7(11):1695.

Tanner Z, Lachowsky N, Ding E, Samji H, Hull MW, Cescon A, Patterson SE, Chia J, Leslie A, Raboud JM, Loutfy MR, Cooper C, Klein MB, Machouf N, Tsoukas C, Montaner J, Hogg RS. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect Dis. 2016;16(1):590.

Thorne A, Chowdhury F, Singer J, Keynan Y, Fowke KR, Cooper C, CIHR Canadian HIV Trials Network (CTN) Influenza Vaccine Research Group. Comparison of hemagglutination inhibition and microbead array assays for the measurement of influenza antibody levels in HIV-infected adults. Vaccine. 2016 June;34(31):3584-91.

Research Publications 2015

Abraham AG, Althoff KN, Jing Y, Estrella MM, Kitahata MM, Wester CW, Bosch RJ, Crane H, Eron J, Gill MJ, Horberg MA, Justice AC, Klein M, Mayor AM, Moore RD, Palella FJ, Parikh CR, Silverberg MJ, Golub ET, Jacobson LP, Napravnik S, Lucas GM; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015 Mar 15;60(6):941-9.

Abelsohn K, Benoit AC, Conway T, Cioppa L, Smith S, Kwaramba G, Lewis J, Nicholson VJ, O’Brien N, Carter A, Shurgold J, Kaida A, de Pokomandy A, Loutfy MR; the CHIWOS Research Team. “Hear(ing) new voices”: peer reflections from community-based survey development with women living with HIV. Prog Community Health Partnersh. 2015;9(4):561–9.

Angel JB, Routy JP, Graziani GM, Tremblay CL. The effect of therapeutic HIV vaccination with ALVAC-HIV with or without Remune on the size of the viral reservoir (a CTN 173 substudy). J Acquir Immune Defic Syndr. 2015 Oct 1;70(2):122–8.

Cao W, Vyboh K, Routy B, Chababi-Atallah M, Lemire B, Routy JP. Imatinib for highly chemoresistant Kaposi sarcoma in a patient with long-term HIV control: a case report and literature review. Curr Oncol. 2015 Oct;22(5):e395–9.

Carter A, Greene S, Nicholson VJ, O’Brien N, Dahlby J, de Pokomandy A, Loutfy MR, Kaida A; Team OBOTCR. “It’s a very isolating world”: the journey to HIV care for women living with HIV in British Columbia, Canada. Gend Place Cult. 2015 Sep 7 [epub]. doi: 10.1080/0966369X.2015.1073701.

Cescon A, Patterson SE, Davey C, Ding E, Raboud JM, Chan K, Loutfy MR, Cooper C, Burchell AN, Palmer AK, Tsoukas C, Machouf N, Klein MB, Rourke SB, Rachlis A, Hogg RS, Montaner JSG; the CANOC Collaboration. Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. J Int AIDS Soc. 2015 Apr 10;18(1).

Cooper C, Rollet-Kurhajec KC, Young J, Vasquez C, Tyndall M, Gill J, Pick N, Walmsley SL, Klein MB; Canadian Co-infection Cohort Study Investigators. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients. HIV Med. 2015 Jan;16(1):24–31.

Costiniuk CT, Gosnell BI, Manzini TC, Plessis Du CN, Moosa MYS. Tuberculous drug-induced liver injury and treatment re-challenge in human immunodeficiency virus co-infection. J Glob Infect Dis. 2015 Oct;7(4):151–6.

Cote J, Bourbonnais A, Rouleau G, Ramirez-Garcia P, Couture M, Masse B, Tremblay C. Psychosocial profile and lived experience of HIV-infected long-term nonprogressors: a mixed method study. J Assoc Nurses AIDS Care. 2015 Mar-Apr;26(2):164-75.

Côté J, Cossette S, Ramirez-Garcia P, de Pokomandy A, Worthington C, Gagnon MP, Auger P, Boudreau F, Miranda J, Guéhéneuc YG, Tremblay CL. Evaluation of a web-based tailored intervention (TAVIE en santé) to support people living with HIV in the adoption of health promoting behaviours: an online randomized controlled trial protocol. BMC Public Health. 2015;15(1):1042.

Cubas R, van Grevenynghe J, Wills S, Kardava L, Santich BH, Buckner CM, Muir R, Tardif V, Nichols C, Procopio F, He Z, Metcalf T, Ghneim K, Locci M, Ancuta P, Routy JP, Trautmann L, Li Y, McDermott AB, Koup RA, Petrovas C, Migueles SA, Connors M, Tomaras GD, Moir S, Crotty S, Haddad EK. Reversible reprogramming of circulating memory T follicular helper cell function during chronic HIV infection. J Immunol. 2015 Dec 4;195(12):5625–36.

DaFonseca S, Niessl J, Pouvreau S, Wacleche VS, Gosselin A, Cleret-Buhot A, Bernard N, Tremblay CL, Jenabian MA, Routy JP, Ancuta P. Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART. Retrovirology. BioMed Central; 2015;12(1):38.

Depatureaux A, Leblanc R, Moisi D, Brenner B, Wainberg MA. The first report of HIV-1 group O infection in Canada. J Infect Dis Ther. 2015 Feb 26;03(01).

Depatureaux A, Mesplède T, Quashie P, Oliveira M, Moisi D, Plantier JC, Brenner B, Wainberg MA. HIV-1 group O resistance against integrase inhibitors. J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):9–15.

Duncan KC, Chan KJ, Chiu CG, Montaner JS, Coldman AJ, Cescon A, Au-Yeung CG, Wiseman SM, Hogg RS, Press NM. HAART slows progression to anal cancer in HIV-infected MSM. AIDS. 2015 Jan 28;29(3):305-11.

Durand M, Wang Y, Venne F, Lelorier J, Tremblay CL, Abrahamowicz M. Diagnostic accuracy of algorithms to identify hepatitis C status, AIDS status, alcohol consumption and illicit drug use among patients living with HIV in an administrative healthcare database. Pharmacoepidemiol Drug Saf. 2015 Sep;24(9):943–50.

El-Far M, Ancuta P, Routy JP, Zhang Y, Bakeman W, Bordi R, DaFonseca S, Said EA, Gosselin A, Tep TS, Eichbaum Q, van Grevenynghe J, Schwartz O, Freeman GJ, Haddad EK, Chomont N, Sekaly RP. Nef promotes evasion of HIV-1 infected cells from the CTLA-4-mediated inhibition of T cell activation. J Gen Virol. 2015 Jun;96(Pt 6):1463-77.

Gillis J, Bayoumi AM, Burchell AN, Cooper C, Klein MB, Loutfy MR, Machouf N, Montaner JSG, Tsoukas C, Hogg RS, Raboud JM. Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study. BMC Infect Dis. 2015 Oct 26;15(1):1.

Gosnell BI, Costiniuk CT, Mathaba E, Moosa MYS. Trichomonas vaginalis associated with chronic penile ulcers and multiple urethral fistulas. Am J Trop Med Hyg. 2015 May 6;92(5):943–4.

Graziani GM, Angel JB. Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions. J Int AIDS Soc. 2015 Nov 9;18(1):1–16.

Isitman G, Lisovsky I, Tremblay-McLean A, Parsons MS, Shoukry NH, Wainberg MA, Bruneau J, Bernard NF. Natural killer cell education does not affect the magnitude of granzyme B delivery to target cells by antibody-dependent cellular cytotoxicity. AIDS. 2015 Jul 31;29(12):1433–43.

Jenabian MA, El-Far M, Vyboh K, Kema I, Costiniuk CT, Thomas R, Baril JG, LeBlanc R, Kanagaratham C, Radzioch D, Allam O, Ahmad A, Lebouche B, Tremblay C, Ancuta P, Routy JP, for the Montreal Primary infection and Slow Progressor Study Groups. Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection. J Infect Dis. 2015 Aug 1;212(3):355-66.

Kaida A, Carter A, de Pokomandy A, Patterson S, Proulx-Boucher K, Nohpal A, Sereda P, Colley G, O’Brien N, Thomas-Pavanel J, Beaver K, Nicholson VJ, Tharao W, Fernet M, Otis J, Hogg RS, Loutfy M; CHIWOS Research Team. Sexual inactivity and sexual satisfaction among women living with HIV in Canada in the context of growing social, legal and public health surveillance. J Int AIDS Soc. 2015 Dec 1;18(Suppl 5):20284.

Kennedy VL, Loutfy MR, Brophy J, Ontario HIV Infant Feeding Working Group. Issues in applying a harm reduction approach to breastfeeding in the context of maternal HIV. Clin Infect Dis. 2015 Feb 15;60(4):672-4.

Keynan Y, Rueda ZV, Bresler K, Becker M, Kasper K. HLA B51 is associated with faster AIDS progression among newly diagnosed HIV-infected individuals in Manitoba, Canada. Int J Immunogenet. 2015 Aug 11;42(5):336–40.

Lima VD, Reuter A, Harrigan PR, Lourenço L, Chau W, Hull MW, Mackenzie L, Guillemi S, Hogg RS, Barrios R, Montaner JSG. Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes. AIDS. 2015 Sep 10;29(14):1871–82.

Lisovsky I, Isitman G, Bruneau J, Bernard NF. Functional analysis of NK cell subsets activated by 721.221 and K562 HLA-null cells. J Leukoc Biol. 2015 Apr;97(4):761–7.

Lisovsky I, Isitman G, Song R, DaFonseca S, Tremblay-McLean A, Lebouche B, Routy JP, Bruneau J, Bernard NF. A higher frequency of NKG2A+ than of NKG2A-NK cells responds to autologous HIV-infected CD4 cells irrespective of whether or not they coexpress KIR3DL1. J Virol. 2015 Oct;89(19):9909–19.

Lu W, Mehraj V, Vyboh K, Cao W, Li T, Routy JP. CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients. J Int AIDS Soc. 2015;18(1):20052.

Margolick JBApuzzo LSinger JWong HLee TGallant JEEl-Helou PLoutfy MRRachlis AFraser CKasper KTremblay CTossonian HConway B. A randomized trial of time-limited antiretroviral therapy in acute/early HIV infection. PLoS One. 2015 Nov 24;10(11):e0143259.

Mendelsohn JB, Calzavara L, Daftary A, Mitra S, Pidutti J, Allman D, Bourne A, Loutfy M, Myers T. A scoping review and thematic analysis of social and behavioural research among HIV-serodiscordant couples in high-income settings. BMC Public Health. 2015 Mar 13;15:241.

Milloy MJ, Marshall B, Kerr T, Richardson L, Hogg R, Guillemi S, Montaner JS, Wood E. High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs. Drug Alcohol Rev. 2015 Mar;34(2):135-40.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group, the Royal Free Hospital Clinic Cohort, and the INSIGHT, SMART, and ESPRIT study groups. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015 Mar 31;12(3):e1001809–31.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay CL, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015 Dec 3;373(23):2237–46.

Moqueet N, Infante-Rivard C, Platt R, Young J, Cooper C, Hull MW, Walmsley SL, Klein MB. Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in aboriginals in Canadian HIV-hepatitis C co-infected individuals. IJMS. 2015 Mar;16(3):6496–512.

Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Krajden M, van Niekerk DJ, Coldman AJ. Reduction in cervical dysplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis. Int J Cancer. 2015 Jun 3 [epub ahead of print]. doi: 10.1002/ijc.29508.

Ostrowski M, Benko E, Yue FY, Kim CJ, Huibner S, Lee T, Singer J, Pankovich J, Laeyendecker O, Kaul R, Kandel G, Kovacs C. Intensifying antiretroviral therapy with raltegravir and maraviroc during early human immunodeficiency virus (HIV) infection does not accelerate HIV reservoir reduction. Open Forum Infect Dis. 2015 Sep 22;2(4):ofv138.

Ouellet E, Durand M, Guertin JR, Lelorier J, Tremblay CL. Cost effectiveness of “on demand” HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada. Can J Infect Dis Med Microbiol. 2015 Jan;26(1):23–9.

Patterson S, Cescon A, Samji H, Chan K, Zhang W, Raboud J, Burchell AN, Cooper C, Klein MB, Rourke SB, Loutfy MR, Machouf N, Montaner JS, Tsoukas C, Hogg RS; CANOC collaboration. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis. 2015 Jul 17;15:274.

Quashie PK, Han YS, Hassounah S, Mesplède T, Wainberg MA. Structural studies of the HIV-1 integrase protein: compound screening and characterization of a DNA-binding inhibitor. PLOS ONE. 2015;10(6):e0128310.

Rollet-Kurhajec KC, Moodie EEM, Walmsley SL, Cooper C, Pick N, Klein MB; Canadian Co-infection Cohort Study. Hepatic fibrosis progression in HIV-hepatitis C virus co-infection – the effect of sex on risk of significant fibrosis measured by aspartate-to-platelet ratio index. PLoS ONE. 2015 Jun 19;10(6):e0129868.

Saarela O, Stephens DA, Moodie EEM, Klein MB. On Bayesian estimation of marginal structural models. Biom. 2015 Feb 10;71(2):279–88.

Samji H, Taha TE, Moore D, Burchell AN, Cescon A, Cooper C, Raboud JM, Klein MB, Loutfy MR, Machouf N, Tsoukas C, Montaner JSG, Hogg RS; CANOC collaboration. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada. HIV Med. 2015 Feb;16(2):76–87.

Serghides L, Finney CA, Ayi K, Loutfy M, Kain KC. Chronic HIV infection impairs nonopsonic phagocytosis of malaria parasites. J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):128-32.

Tan DHS, Szadkowski L, Raboud JM, Yi TJ, Shannon B, Kaul R, Liles WC, Walmsley SL. Effect of intercurrent infections and vaccinations on immune and inflammatory biomarkers among human immunodeficiency virus-infected adults on suppressive antiretroviral therapy. Open Forum Infect Dis. 2015 Apr 1;2(2):ofv036–6.

Tang CC, Isitman G, Bruneau J, Tremblay CL, Bernard NF, Kent SJ, Parsons MS. Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation. Clin Exp Immunol. 2015 Aug;181(2):275–85.

Veillette M, Coutu M, Richard J, Batraville LA, Dagher O, Bernard N, Tremblay C, Kaufmann DE, Roger M, Finzi A. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol. 2015 Jan;89(1):545-51.

Vyboh K, Jenabian MA, Mehraj V, Routy JP. HIV and the gut microbiota, partners in crime: breaking the vicious cycle to unearth new therapeutic targets. J Immunol Res. 2015 Feb 22 [epub ahead of print]. doi: 10.1155.2015.614127.

Wiens MO, Kumbakumba E, Larson CP, Ansermino JM, Singer J, Kissoon N, Wong H, Ndamira A, Kabakyenga J, Kiwanuka J, Zhou G. Postdischarge mortality in children with acute infectious diseases: derivation of postdischarge mortality prediction models. BMJ Open. 2015;5(11):e009449.

Yeung MW, Young J, Moodie E, Rollet-Kurhajec KC, Schwartzman K, Greenaway C, Cooper C, Cox J, Gill J, Hull MW, Walmsley SL, Klein MB. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study. HIV Clin Trials. 2015 May;16(3):100–10.

Young J, Mucsi I, Rollet-Kurhajec KC, Klein MB; Canadian Co-infection Cohort. Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C. HIV Med. 2015 Aug 26 [epub ahead of print]. doi: 10.1111/hiv.12305.

Research Publications 2014

Althoff KN, Rebeiro P, Brooks JT, Buchacz K, Gebo K, Martin J, Hogg R, Thorne JE, Klein M, Gill MJ, Sterling TR, Yehia B, Silverberg MJ, Crane H, Justice AC, Gange SJ, Moore R, Kitahata MM, Horberg MA, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Disparities in the quality of HIV care when using US department of health and human services indicators. Clin Infect Dis. 2014 Apr;58(8):1185-9.

Balfour L, Spaans JN, Fergusson D, Huff H, Mills EJ, la Porte CJ, Walmsley S, Singhai N, Rosenes R, Tremblay N, Gill MJ, Loemba H, Conway B, Rachlis A, Ralph E, Loutfy M, Mallick R, Moorhouse R, William Cameron D. Micronutrient deficiency and treatment adherence in a randomized controlled trial of micronutrient supplementation in ART-naïve persons with HIV. PLoS One [Internet]. 2014 Jan 21;9(1).

Barnett PG, Chow A, Joyce VR, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Cameron W, Sculpher M, Youle M, Anis AH, Owens DK. Effect of management strategies and clinical status on costs of care for advanced HIV . Am J Manag Care. 2014 May;20(5):e129-37.

Bitnun A, Brophy J, Samson L, Alimenti A, Kakkar F, Lamarre V, Moore D, Karatzios C, Seigel S, Sauve L, Vaudry W, Yudin MH, Money D. Prevention of vertical HIV transmission and management of the HIV-exposed infant in canada in 2014. Can J Infect Dis Med Microbiol. 2014 Mar;25(2):75-7.

Blais M, Fernet M, Proulx-Boucher K, Lapointe N, Samson J, Otis J, Racicot C, Rodrigue C, Lebouche B. Family quality of life in families affected by HIV: The perspective of HIV-positive mothers. AIDS Care. 2014;26 Suppl 1:S21-8.

Carter A, Greene S, Nicholson V, O’Brien N, Sanchez M, Pokomandy AD, Loutfy M, Kaida A. Breaking the glass ceiling: Increasing the meaningful involvement of women living with HIV/AIDS (MIWA) in the design and delivery of HIV/AIDS services. Health Care Women Int. 2014 Sep 25:1-29.

Cescon A, Chan K, Raboud JM, Burchell AN, Forrest JI, Klein MB, Loutfy MR, Machouf N, Montaner JS, Tsoukas C, Hogg RS, Cooper C, CANOC Collaboration. Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history. AIDS. 2014 Jan 2;28(1):121-7.

Cescon A, Kanters S, Brumme CJ, Lepik KJ, Forrest JI, Hull M, Samji H, Nosyk B, Harrigan PR, Hogg RS, Montaner JS. Trends in plasma HIV-RNA suppression and antiretroviral resistance in british columbia, 1997-2010. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):107-14.

Cooper C, Klein M. HIV/hepatitis C virus coinfection management: changing guidelines and changing paradigms. HIV Med. 2014 Nov;15(10):621-4. doi: 10.1111/hiv.12161. Epub 2014 May 6. PMID: 24802099 [PubMed – in process].

Cooper C, Rollet-Kurhajec K, Young J, Vasquez C, Tyndall M, Gill J, Pick N, Walmsley S, Klein MB. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/Hepatitis C virus-coinfected patients. HIV Medicine May 2014.

Cooper C, Rollet-Kurhajec K, Young J, Vasquez C, Tyndall M, Gill J, Pick N, Walmsley S, Klein M; the Canadian Co-infection Cohort Study Investigators. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients. HIV Med. 2014 May 18. doi: 10.1111/hiv.12168. [Epub ahead of print] PMID: 24837567 [PubMed – as supplied by publisher].

Costiniuk CT, Jenabian MA. The lungs as anatomical reservoirs of HIV infection. Rev Med Virol. 2014 Jan;24(1):35–54.

Cox J, Maurais E, Hu L, Moodie EE, Law S, Bozinoff N, Potter M, Rollet K, Hull M, Tyndall M, Cooper C, Gill J, Saeed S, Klein MB, The Canadian Co-infection Cohort (CTN 222). Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort. Drug Alcohol Depend [Internet]. 2014 Jan 30.

Crouzat F, Benoit A, Kovacs C, Smith G, Taback N, Sandler I, Brunetta J, Chang B, Merkley B, Tilley D, Fletcher D, Kalaria D, Loutfy M. Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19757.

Dieterich D, Rockstroh JK, Orkin C, Gutierrez F, Klein MB, Reynes J, Shukla U, Jenkins A, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, De La Rosa G, Tambuyzer L,Jessner W. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: A phase 3 study. Clin Infect Dis. 2014 Dec 1;59(11):1579-87.

Giesbrecht CJ, Thornton AE, Hall-Patch C, Maan EJ, Cote HC, Money DM, Murray M, Pick N. Select neurocognitive impairment in HIV-infected women: Associations with HIV viral load, hepatitis C virus, and depression, but not leukocyte telomere length. PLoS One. 2014 Mar 4;9(3):e89556.

Gonzalez-Serna A, Chan K, Yip B, Chau W, McGovern R, Samji H, Lima VD, Hogg RS, Harrigan R. Temporal trends in the discontinuation of first-line antiretroviral therapy. J Antimicrob Chemother. 2014 Aug;69(8):2202-9.

Hirsch Allen AJ, Forrest JI, Kanters S, O’Brien N, Salters KA, McCandless L, Montaner JS, Hogg RS. Factors associated with disclosure of HIV status among a cohort of individuals on antiretroviral therapy in british columbia, canada. AIDS Behav. 2014 Jun;18(6):1014-26.

Hull M, Klein M, Shafran S, Tseng A, Giguere P, Cote P, Poliquin M, Cooper C. CIHR Canadian HIV Trials Network coinfection and concurrent diseases core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol [Internet]. 2013 Winter;24(4):217-38.

Kared H, Saeed S, Klein MB, Shoukry NH. CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals. PLoS One. 2014 Jul 9;9(7):e101441.

Kennedy VL, Serghides L, Raboud JM, Su D, Blitz S, Hart TA, Walmsley SL, Angel JB, Smaill FM, Ralph ED, Tharao WE, Loutfy MR, Ontario HIV Fertility Research Team. The importance of motherhood in HIV-positive women of reproductive age in ontario, canada. AIDS Care. 2014;26(6):777-84.

Klein MB, Rollet-Kurhajec KC, Moodie EE, Yaphe S, Tyndall M, Walmsley S, Gill J, Martel-Laferriere V, Cooper C; Canadian Co-infection Cohort Investigators. Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). AIDS. 2014 Aug 24;28(13):1957-65. doi: 10.1097/QAD.0000000000000377. PMID:25259703[PubMed – in process].

Klein MB, Young J, Dunn D, Ledergerber B, Sabin C, Cozzi-Lepri A, Dabis F, Harrigan R, Tan DH, Walmsley S, Gill J, Cooper C, Scherrer AU, Mocroft A, Hogg RS, Smaill F, Canadian-European Clade Collaboration. The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: Acanadian-european collaborative retrospective cohort study. CMAJ Open. 2014 Oct 1;2(4):E318-29.

Klein MB, Lee T, Brouillette MJ, Sheehan NL, Walmsley S, Wong DK, Conway B, Hull M, Cooper C, Haidar S, Vezina S, Annable L, Young S, Zubyk W, Singer J. Citalopram for the prevention of depression and its consequences in HIV-hepatitis C coinfected individuals initiating pegylated interferon/ribavirin therapy: a multicenter randomized double-blind placebo-controlled trial. HIV Clin Trials. 2014 Jul-Aug;15(4):161-75. doi: 10.1310/hct1504-161. PMID: 25143025 [PubMed – indexed for MEDLINE].

Kuo M, Money DM, Alvarez M, Buxton JA, Krajden M, Lester RT, Ogilvie G, Gilbert M. Test uptake and case detection of syphilis, HIV, and hepatitis C among women undergoing prenatal screening in british columbia, 2007 to 2011. J Obstet Gynaecol Can. 2014 Jun;36(6):482-90.

Lebouché B, Jenabian MA, Singer J, Graziani GM, Engler K, Trottier B, Thomas R, Brouillette MJ, Routy JP. The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy – CTN PT006: study protocol for a randomized controlled trial. Trials. 2014 Oct 7;15(1):390. doi: 10.1186/1745-6215-15-390. PMID: 25293882.

Lima VD, Kerr T, Wood E, Kozai T, Salters KA, Hogg RS, Montaner JS. The effect of history of injection drug use and alcoholism on HIV disease progression. AIDS Care. 2014 Jan;26(1):123-9.

Liu T, Howell GT, Turner L, Corace K, Garber G, Cooper C. Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes. Can JGastroenterol Hepatol. 2014 Jul-Aug;28(7):381-4.

Lo Re V,3rd, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR,Kostman JR, Strom BL, Justice AC. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med. 2014 Mar 18;160(6):369-79.

Lourenco L, Lima VD, Heath K, Nosyk B, Gilbert M, Colley G, Consolacion T, Barrios R, Hogg R, Krajden M, Konrad S, Murti M, Nelson J, May-Hadford J, Haggerstone J, Pick N, Gustafson R, Rusch M, Day I, Montaner JS, STOP HIV/AIDS Study Group. Process monitoring of an HIV treatment as prevention program in british columbia, canada. JAcquir Immune Defic Syndr. 2014 Nov 1;67(3):e94-e109.

Loutfy M, Tyndall M, Baril JG, Montaner JS, Kaul R, Hankins C. Canadian consensus statement on HIV and its transmission in the context of criminal law. Can J Infect Dis Med Microbiol. 2014 May;25(3):135-40.

Loutfy MR, Blitz S, Zhang Y, Hart TA, Walmsley SL, Smaill FM, Rachlis AR, Yudin MH, Angel JB, Ralph ED, Tharao W, Raboud JM, Ontario HIV Fertility Research Team. Self-reported preconception care of HIV-positive women of reproductive potential: A retrospective study. J Int Assoc Provid AIDS Care. 2014 Sep;13(5):424-33.

May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D’Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fatkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA, Antiretroviral Cohort Collaboration. Cohort profile: Antiretroviral therapy cohort collaboration (ART-CC). Int J Epidemiol. 2014 Jun;43(3):691-702.

MacKenzie L, Keynan Y, Becker M, Shafer L, Shaw S, Lopko B, Kasper K. The association between ethnicity and Human Leukocyte Antigen (HLA) alleles on late presentation to care and high rates of opportunistic infections in patients with HIV (Human Immunodeficiency Virus). Journal of AIDS and HIV Research.

MacParland SA, Bilodeau M, Grebely J, Bruneau J, Cooper C, Klein M, Sagan S, Choucha N, Balfour L, Bialystok F, Krajden M, Raven J, Roberts E, Russell R, Houghton M, Tyrrell DL, Feld JJ; National CIHR Research Training Program in Hepatitis C. The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era. Can J Gastroenterol Hepatol. 2014 Oct;28(9):481-7. PMID: 25314353 [PubMed – in process].

Money D, Boucoiran I, Wagner E, Dobson S, Kennedy A, Lohn Z, Krajden M, Yoshida EM. Obstetrical and neonatal outcomes among women infected with hepatitis C and their infants. J Obstet Gynaecol Can. 2014 Sep;36(9):785-94.

Money D, Tulloch K, Boucoiran I, Caddy S, Infectious Diseases Committee, Yudin MH, Allen V, Bouchard C, Boucher M, Boucoiran I, Caddy S, Castillo E, Gottlieb H, Kennedy VL, Money D, Murphy K, Ogilvie G, Paquet C, van Schalkwyk J. Guidelines for the care of pregnant women living with HIV and interventions to reduce perinatal transmission: Executive summary. J Obstet Gynaecol Can. 2014 Aug;36(8):721-51.

Montaner JS, Lima VD, Harrigan PR, Lourenco L, Yip B, Nosyk B, Wood E, Kerr T, Shannon K, Moore D, Hogg RS, Barrios R, Gilbert M, Krajden M, Gustafson R, Daly P, Kendall P. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: The “HIV treatment as prevention” experience in a canadian setting. PLoS One. 2014 Feb 12;9(2):e87872.

Moodie EE, Stephens DA, Klein MB. A marginal structural model for multiple-outcome survival data:Assessing the impact of injection drug use on several causes of death in the canadian co-infection cohort. Stat Med. 2014 Apr 15;33(8):1409-25.

Mukonzo JK, Owen JS, Ogwal-Okeng J, Kuteesa RB, Nanzigu S, Sewankambo N, Thabane L, Gustafsson LL, Ross C, Aklillu E. Pharmacogenetic-based efavirenz dose modification: Suggestions for an African population and the different CYP2B6 genotypes. PLoS One [Internet]. 2014 Jan 31;9(1).

Ndumbi P, Gillis J, Raboud J, Cooper C, Hogg RS, Montaner JS, Burchell AN, Loutfy MR, Machouf N, Klein MB, Tsoukas C; Canadian Observational Cohort (CANOC) Collaboration. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy. HIV Med. 2014 Mar;15(3):153-64. doi: 10.1111/hiv.12096. Epub 2013 Oct 31. PMID: 24304582 [PubMed – indexed for MEDLINE].

Ng BE, Moore D, Michelow W, Hogg R, Gustafson R, Robert W, Kanters S, Thumath M, McGuire M, Gilbert M. Relationship between disclosure of same-sex sexual activity to providers, HIV diagnosis and sexual health services for men who have sex with men in vancouver, canada. Can J Public Health. 2014 Apr 16;105(3):e186-91.

Nosyk B, Montaner JS, Colley G, Lima VD, Chan K, Heath K, Yip B, Samji H, Gilbert M, Barrios R, Gustafson R, Hogg RS, STOP HIV/AIDS Study Group. The cascade of HIV care in british columbia, canada, 1996-2011: A population-based retrospective cohort study. Lancet Infect Dis. 2014 Jan;14(1):40-9.

Palmer AK, Cescon A, Chan K, Cooper C, Raboud JM, Miller CL, Burchell AN, Klein MB, Machouf N, Montaner JS, Tsoukas C, Hogg RS, Loutfy MR, CANOC Collaboration. Factors associated with late initiation of highly active antiretroviral therapy among young HIV-positive men and women aged 18 to 29 years in Canada. J Int Assoc Provid AIDS Care [Internet]. 2014 Jan-Feb;13(1):56-62.

Pantalone DW, Horvath KJ, Hart TA, Valentine SE, Kaysen DL. Traumatic revictimization of men who have sex with men living with HIV/AIDS. J Interpers Violence. 2014 Jul 2

Parashar S, Chan K, Milan D, Grafstein E, Palmer AK, Rhodes C, Montaner JS, Hogg RS. The impact of unstable housing on emergency department use in a cohort of HIV-positive people in a canadian setting. AIDS Care. 2014 Jan;26(1):53-64.

Peters L, Neuhaus J, Duprez D, Neaton JD, Tracy R, Klein MB, Mocroft A, Rockstroh J, Dore G, Lundgren JD, INSIGHT SMART Study Group. Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. J Clin Virol. 2014 Jul;60(3):295-300.

Raffi F, Rachlis A, Brinson C, Arasteh K, Górgolas M, Brennan C, Pappa K, Almond S, Granier C, Nichols WG, Cuffe RL, Eron J Jr, Walmsley S. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS. 2014 Nov 9. [Epub ahead of print] PMID:25387312.

Routy JP, Angel J, Patel M, Kanagaratham C, Radzioch D, Kema I, Gilmore N, Ancuta P, Singer J, Jenabian MA. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med. 2014 Jun 2. doi: 10.1111/hiv.12171. [Epub ahead of print] PMID: 24889179

Samji H, Taha T, Moore D, Burchell A, Cescon A, Cooper C, Raboud J, Klein M, Loutfy M, Machouf N, Tsoukas C, Montaner J, Hogg R; Canadian Observational Cohort (CANOC) Collaboration; Canadian Observational Cohort CANOC Collaboration. Predictors of unstructured antiretroviral treatment interruption and resumption among HIV-positive individuals in Canada. HIV Med. 2014 Sep 1. doi: 10.1111/hiv.12173. [Epub ahead of print] PMID:25174373.

Samji H, Chen Y, Salters K, Montaner JS, Hogg RS. Correlates of unstructured antiretroviral treatment interruption in a cohort of HIV-positive individuals in british columbia. AIDS Behav. 2014 Nov;18(11):2240-8.

Schilder AJ, Anema A, Pai J, Rich A, Miller CL, Chan K, Strathdee SA, Moore D, Montaner JS, Hogg RS. Association between childhood physical abuse, unprotected receptive anal intercourse and HIV infection among young men who have sex with men in vancouver, canada. PLoS One. 2014 Jun 25;9(6):e100501.

Schnitzer M, Moodie E, Van der Laan M, Platt R, Klein M. Modeling the impact of Hepatitis C viral clearance on End-stage liver disease in an HIV co-infected Cohort with targeted maximum likelihood estimation. Biometrics MARCH 2014.

Tan DH, Raboud J, Szadkowski L, Yi TJ, Shannon B, Kaul R, Liles WC, Walmsley S. HSV-2 serostatus is not associated with inflammatory or metabolic markers in ART-treated HIV. AIDS Res Hum Retroviruses. 2014 Nov 16. [Epub ahead of print] PMID:25399537.

Werker GR, Sharif B, Sun H, Cooper C, Bansback N, Anis AH. Optimal timing of influenza vaccination in patients with human immunodeficiency virus: A Markov cohort model based on serial study participant hemoagglutination inhibition titers. Vaccine [Internet]. 2014 Feb 3; 32(6):677-84.

Wagner AC, Hart TA, McShane KE, Margolese S, Girard TA. Health care provider attitudes and beliefs about people living with HIV: Initial validation of the health care provider HIV/AIDS stigma scale (HPASS). AIDS Behav. 2014 Dec;18(12):2397-408.

Wagner AC, Ivanova EL, Hart TA, Loutfy MR. Examining the traits-desires-intentions-behavior (TDIB) model for fertility planning in women living with HIV in ontario,canada. AIDS Patient Care STDS. 2014 Nov;28(11):594-601.

Yam KK, Gipson E, Klein M, Walmsley S, Haase D, Halperin S, Scheifele D, Ward BJ, Cooper C. High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine. J Clin Immunol. 2014 Aug;34(6):655-62.

Zanet DL, Thorne A, Singer J, Maan EJ, Satthe B, Le Campion A, Soudeyns H, Pick N, Murray M, Money DM, Cote HC, for the CIHR Emerging Team Grant on HIV Therapy and Aging: CARMA. Association between short leukocyte telomere length and HIV infection in a cohort study: No evidence of a relationship with antiretroviral therapy. Clin Infect Dis [Internet]. 2014 Feb 25.

Research Publications 2013

Andany N, Loutfy MR. HIV protease inhibitors in pregnancy : Pharmacology and clinical use. Drugs [Internet]. 2013 Mar;73(3):229-47.

Antoniou T, Gillis J, Loutfy MR, Cooper C, Hogg RS, Klein MB, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Raboud JM, The Canadian Observational Cohort (CANOC) collaboration. Impact of the data collection on adverse events of anti-HIV drugs cohort study on abacavir prescription among treatment-naive, HIV-infected patients in Canada. J Int Assoc Provid AIDS Care [Internet]. 2013 Jul 25.

Asahchop EL, Wainberg MA, Oliveira M, Xu H, Brenner BG, Moisi D, Ibanescu IR, Tremblay C. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. AIDS [Internet]. 2013 Mar 27;27(6):879-87.

Bayoumi AM, Barnett PG, Joyce VR, Griffin SC, Sun H, Bansback NJ, Holodniy M, Sanders G, Brown ST, Kyriakides TC, Angus B, Cameron DW, Anis AH, Sculpher M, Owens DK. Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. J Acquir Immune Defic Syndr [Internet]. 2013 Dec 1;64(4):382-91.

Beauchamp E, Rollet K, Walmsley S, Wong DK, Cooper C, Klein MB, Canadian Co-infection Cohort Study (CTN222). Missed opportunities for hepatocellular carcinoma screening in an HIV/hepatitis C virus-coinfected cohort. Clin Infect Dis [Internet]. 2013 Nov;57(9):1339-42.

Benoit AC, Light L, Burchell AN, Gardner S, Rourke SB, Wobeser W, Loutfy MR; the OHTN Cohort Study Team; the Ontario CHIWOS Research Team. Demographic and clinical factors correlating with high levels of psychological distress in HIV-positive women living in Ontario, Canada. AIDS Care. 2013 Nov 12.

Bernier A, Cleret-Buhot A, Zhang Y, Goulet JP, Monteiro P, Gosselin A, DaFonseca S, Wacleche VS, Jenabian MA, Routy JP, Tremblay C, Ancuta P. Transcriptional profiling reveals molecular signatures associated with HIV permissiveness in Th1Th17 cells and identifies peroxisome proliferator-activated receptor gamma as an intrinsic negative regulator of viral replication. Retrovirology [Internet]. 2013 Dec 21;10:160,4690-10-160.

Blitz S, Baxter J, Raboud J, Walmsley S, Rachlis A, Smaill F, Ferenczy A, Coutlee F, Hankins C, Money D, for the Canadian Women’s HIV Study Group. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis. 2013 May 24.

Breton G, Chomont N, Takata H, Fromentin R, Ahlers J, Filali-Mouhim A, Riou C, Boulassel MR, Routy JP, Yassine-Diab B, Sekaly RP. Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection. J Immunol [Internet]. 2013 Sep 1;191(5):2194-204.

Brunet L, Moodie EE, Rollet K, Cooper C, Walmsley S, Potter M, Klein MB, for the Canadian Co-infection Cohort Investigators. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: A longitudinal cohort analysis. Clin Infect Dis [Internet]. 2013 Jul 4.

Carter AJ, Bourgeois S, O’Brien N, Abelsohn K, Tharao W, Greene S, Margolese S, Kaida A, Sanchez M, Palmer AK, Cescon A, de Pokomandy A, Loutfy MR, CHIWOS Research Team. Women-specific HIV/AIDS services: identifying and defining the components of holistic service delivery for women living with HIV/AIDS. J Int AIDS Soc. 2013 Jan 11;16(1):17433.

Cescon A, Patterson S, Chan K, Palmer AK, Margolese S, Burchell AN, Cooper C, Klein MB, Machouf N, Montaner JS, Tsoukas C, Hogg RS, Raboud JM, Loutfy MR, CANOC Collaboration. Gender differences in clinical outcomes among HIV-positive individuals on antiretroviral therapy in canada: A multisite cohort study. PLoS One [Internet]. 2013 Dec 31;8(12):e83649.

Costiniuk CT, Kovacs C, Routy JP, Singer J, Gurunathan S, Sekaly RP, Angel JB. Short communication: Human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy. AIDS Res Hum Retroviruses [Internet]. 2013 Feb;29(2):266-9.

Donahue DA, Wainberg MA. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology [Internet]. 2013 Feb 1;10:11,4690-10-11.

Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013 May 1; 309(17):1793-802.

El-Far M, Isabelle C, Chomont N, Bourbonniere M, Fonseca S, Ancuta P, Peretz Y, Chouikh Y, Halwani R, Schwartz O, Madrenas J, Freeman GJ, Routy JP, Haddad EK, Sekaly RP. Down-regulation of CTLA-4 by HIV-1 nef protein. PLoS One [Internet]. 2013;8(1):e54295.

Finney CA, Ayi K, Wasmuth JD, Sheth PM, Kaul R, Loutfy M, Kain KC, Serghides L. HIV infection deregulates tim-3 expression on innate cells: combination antiretroviral therapy results in partial restoration. J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):161-167.

Han YS, Xiao WL, Quashie PK, Mesplede T, Xu H, Deprez E, Delelis O, Pu JX, Sun HD, Wainberg MA. Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors. Antiviral Res [Internet]. 2013 Jun;98(3):441-8.

Hull MW, Rollet K, Klein MB, Canadian Co-infection Cohort Investigators. Reply to mandorfer et al. Clin Infect Dis [Internet]. 2013 Mar;56(6):905-6.

Hull M, Klein M, Shafran S, Tseng A, Giguere P, Cote P, Poliquin M, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol [Internet]. 2013 Winter; 24(4):217-38.

Jenabian MA, Nicolette CA, Tcherepanova IY, Debenedette MA, Gilmore N, Routy JP. Impact of autologous dendritic cell-based immunotherapy (AGS-004) on B and T cell subset changes and immune activation in HIV-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2013 Sep 6.

Jenabian MA, Seddiki N, Yatim A, Carriere M, Hulin A, Younas M, Ghadimi E, Kok A, Routy JP, Tremblay A, Sevigny J, Lelievre JD, Levy Y. Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection. PLoS Pathog [Internet]. 2013 Apr;9(4):e1003319.

Jenabian MA, Patel M, Kema I, Kanagaratham C, Radzioch D, Thebault P, Lapointe R, Tremblay C, Gilmore N, Ancuta P, Routy JP. Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One [Internet]. 2013 Oct 16;8(10):e78146.

Jenabian MA, Nicolette CA, Tcherepanova IY, Debenedette MA, Gilmore N, Routy JP. Impact of autologous dendritic cell-based immunotherapy (AGS-004) on B- and T-cell subset changes and immune activation in HIV-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr [Internet]. 2013 Dec 1;64(4):345-50.

Kelly EM, Cooper CL. Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy: An analysis of trial effect. Eur J Gastroenterol Hepatol [Internet]. 2013 May 4

Klein MB, Rollet KC, Saeed S, Cox J, Potter M, Cohen J, Conway B, Cooper C, Cote P, Gill J, Haase D, Haider S, Hull M, Moodie E, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S, Canadian HIV-HCV Cohort Investigators. HIV and hepatitis C virus co-infection in Canada: Challenges and opportunities for reducing preventable morbidity and mortality. HIV Med [Internet]. 2013 Jan;14(1):10-20.

Klein MB, Rollet KC, Hull M, Cooper C, Walmsley S, Conway B, Pick N, Canadian Co-infection Cohort Study (CTN222) Investigators. Who needs direct-acting antivirals for HCV? challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals. Antivir Ther [Internet]. 2013;18(5):717-21.

Lebouche B, Engler K, Levy JJ, Gilmore N, Spire B, Rozenbaum W, Routy JP. Minimal interference: A basis for selecting ART for prevention with positives. AIDS Care [Internet]. 2013 Feb 11.

Lebouche B, Engler K, Levy JJ, Gilmore N, Spire B, Rozenbaum W, Lacene T, Routy JP. French HIV experts on early antiretroviral treatment for prevention: Uncertainty and heterogeneity. J Int Assoc Provid AIDS Care [Internet]. 2013 Jun 12.

Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Klein MB; CANOC Collaboration. Predictors of CD4;CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy. PLoS One. 2013 Oct 30;8(10).

Logie C, James L, Tharao W, Loutfy M. Associations between HIV-related stigma, racial discrimination, gender discrimination, and depression among HIV-positive african, caribbean, and black women in ontario, canada. AIDS Patient Care STDS [Internet]. 2013 Feb;27(2):114-22.

Loutfy MR, Sherr L, Sonnenberg-Schwan U, Walmsley SL, Johnson M, D’Arminio Monforte A; Women for Positive Action. Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc. 2013 Oct 1;16(1):18509.

Loutfy MR, Sonnenberg-Schwan U, Margolese S, Sherr L, Women for Positive Action. A review of reproductive health research, guidelines and related gaps for women living with HIV. AIDS Care [Internet]. 2013;25(6):657-66.

Loutfy MR, Wu W, Letchumanan M, Bondy L, Antoniou T, Margolese S, Zhang Y, Rueda S, McGee F, Peck R, Binder L, Allard P, Rourke SB, Rochon PA. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS One [Internet]. 2013;8(2):e55747.

Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology [Internet]. 2013 Feb 22;10:22,4690-10-22.

Oliveira M, Mesplede T, Quashie PK, Moisi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS. 2014 Mar 27;28(6):813-9.

Parsons MS, Center RJ, Routy JP, Rouleau D, Leblanc R, Wainberg MA, Tremblay CL, Zannou MD, Kent SJ, Grant MD, Bernard NF. Short communication: Antibody responses to human immunodeficiency virus envelope from infections with multiple subtypes utilize the 1F7-idiotypic repertoire. AIDS Res Hum Retroviruses [Internet]. 2013 May;29(5):778-83.

Quashie PK, Mesplede T, Wainberg MA. Evolution of HIV integrase resistance mutations. Curr Opin Infect Dis [Internet]. 2013 Feb;26(1):43-9.

Quashie PK, Mesplede T, Wainberg MA. HIV drug resistance and the advent of integrase inhibitors. Curr Infect Dis Rep [Internet]. 2013 Feb;15(1):85-100.

Rodrigues-Coutlee C, Archambault J, Money D, Ramanakumar AV, Raboud J, Hankins C, Koushik A, Richardson H, Brassard P, Franco EL, Coutlee F, Canadian Women’s HIV Study Group. Human papillomavirus type 56 polymorphism in Canadian women with and without cervical lesions. J Clin Virol [Internet]. 2013 Dec;58(4):660-5.

Scheifele DW, Dionne M, Ward BJ, Cooper C, Vanderkooi OG, Li Y, Halperin SA, PHAC/CIHR Influenza Research Network. Safety and immunogenicity of 2010-2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: Results of a randomized trial. Hum Vaccin Immunother [Internet]. 2013 Jan;9(1):136-43.

Slayter KL, Singer J, Lee TC, Kayhty H, Schlech WF. Immunization against pneumococcal disease in HIV-infected patients: Conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147). Int J STD AIDS [Internet]. 2013 Mar 27.

Sloan RD, Kuhl BD, Mesplede T, Munch J, Donahue DA, Wainberg MA. Productive entry of HIV-1 during cell-to-cell transmission via dynamin-dependent endocytosis. J Virol [Internet]. 2013 Jul;87(14):8110-23.

Tan DH, Raboud JM, Kaul R, Brunetta J, Kaushic C, Kovacs C, Lee E, Leutkehoelter J, Rachlis A, Smaill F, Smieja M, Walmsley SL. Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection. Clin Infect Dis. 2013 Apr 25.

Vasquez C, Lioznov D, Nikolaenko S, Yatsishin S, Lesnikova D, Cox D, Pankovich J, Rosenes R, Wobeser W, Cooper C, St Petersburg-CIHR Canadian HIV Trials Network Collaboration. Gender disparities in HIV risk behavior and access to health care in St. Petersburg, Russia. AIDS Patient Care STDS [Internet]. 2013 May;27(5):304-10.

Vandergeeten C, Fromentin R, Dafonseca S, Lawani MB, Sereti I, Lederman MM, Ramgopal M, Routy JP, Sekaly RP, Chomont N. Interleukin-7 promotes HIV persistenc during antiretroviral therapy. Blood. 2013 May 23;121(21):4321-9.

Wainberg MA. Combination therapies, effectiveness, and adherence in patients with HIV infection: Clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir. HIV AIDS (Auckl) [Internet]. 2013;5:41-9.

Yi TJ, Walmsley S, Szadkowski L, Raboud J, Rajwans N, Shannon B, Kumar S, Kain KC, Kaul R, Tan DH. A randomized controlled pilot trail of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis. 2013 Nov;57(9):1331-8.

Research Publications 2012

Articles on CTN studies

January 1, 2012 – December 31, 2012

Asahchop EL, Wainberg MA, Sloan RD, Tremblay CL. “Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.” Antimicrobial Agents and Chemotherapy. 2012. 

Bedimo R, Kyriakides T, Brown S, Weidler J, Lie Y, Coakley E, and Holodniy M.“Predictive value of HIV-1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment-experienced patients.” HIV Medicine. 2012. doi: 10.1111/j.1468-1293.2011.00981.x

Boulassel MR, Chomont N, Pai NP, Gilmore N, Sékaly RP, Routy JP. “CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.” J Clin Virol. 2012 Jan;53(1):29-32. Epub 2011 Oct 22.

Cooper C, Klein M, Walmsley S, Haase D, MacKinnon-Cameron D, Marty K, Li Y, Smith B, Halperin S, Law B, Scheifele D, PHAC CIHR Influenza Research Network.“High-level immunogenicity is achieved with adjuvanted pandemic H1N1 vaccine and improved with booster dosing in a randomized trial of HIV-infected adults.” HIV Clin Trials. 2012; Jan 13(1):23-32

Cui Q, Robinson L, Elston D, Smaill F, et al. “Safety and tolerability of varenicline tartrate (Champix®/Chantix®) for smoking cessation in HIV-infected subjects: A pilot open-label study.” AIDS Patient Care and STDs. 2012 26(1): 12-19.

Dhalla S, Poole G, Singer J, Patrick DM, Kerr T. “Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-positive injection drug users.” Psychol Health Med. 2012 17(2):223-234.

Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, Klein M, Machouf N, Montaner JS, Rourke S, Tsoukas C, Hogg B, Raboud J; CANOC Collaboration. “Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.” J Infect Dis. 2012 Apr 15;205(8):1230-8.

Hull M, Rollet K, Moodie K, Walmsley, Cox J, Potter M; The Canadian co-infection cohort study investigators. “Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/HCV co-infected patients.” AIDS. 2012.

Hull MW, Rollet K, Odueyungbo A, Saeed S, Potter M, Cox J; Canadian Co-infection Cohort Investigators. “Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus.”Clinical Infect Dis. 2012 54(12):1798-1805.

Joyce VR, Barnett PG, Chow A, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Kyriakides TC, Cameron DW, Youle M, Sculpher M, Anis AH, Owens DK. “Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: A randomized, controlled trial.” Med Decis Making2012; 32(1):70-82.

Kamya P, Tallon B, Melendez-Pena C, Parsons MS, Migueles SA, Connors M; Investigators of the canadian cohort of HIV infected slow progressors. “Inhibitory killer immunoglobulin-like receptors to self HLA-B and HLA-C ligands contribute differentially to natural killer cell functional potential in HIV infected slow progressors.” 2012. Clinical Immunology 143(3):246-255.

Klein M, Rollet K, Saeed S, Cox J, Potter M, Cohen J; Canadian HIV-HCV Cohort Investigators. “HIV and hepatitis C virus coinfection in Canada: Challenges and opportunities for reducing preventable morbidity and mortality.” HIV Medicine. 2012.

Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, Harris M, Trottier S, Singer J, Chomont N, Sékaly RP, Boulassel MR. “Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical trial.” HIV Medicine 2012.

Raboud J, Anema A, Su D, Klein MB, Zakaryan A, Swan T, Palmer A, Hosein S, Loutfy MR, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Hogg RS, Cooper C; Canadian Observational Cohort (CANOC) Collaboration. “Relationship of chronic hepatitis C infection to rates of AIDS-defining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy.” HIV Clin Trials. 2012 Mar-Apr;13(2):90-102.

Spaans JN, Routy JP, Tremblay C, Singer J, Bernard N, Gurunathan S, Sékaly RP, Angel JB. “Optimizing the efficiency of therapeutic HIV vaccine trials: A case for CTN 173.” J Trials in Vac. Feb 2012. [E-pub ahead of print]

Articles by CTN Investigators

January 1, 2012 – December 31, 2012

Cooper C, Klein M, Walmsley S, Haase D, MacKinnon-Cameron D, Marty K, Li Y, Smith B, Halperin S, Law B, Scheifele; PHAC CIHR Influenza Research Network.“High-level immunogenicity is achieved with adjuvanted pandemic H1N1 vacccine and improved with booster dosing in a randomized trial of HIV-infected adults. ” HIV Clin Trials. 2012; Jan 13(1):23-32

Chege D, Kovacs C, la Porte C, Ostrowski M, Raboud J, Su D, Kandel G, Brunetta J, Kim CJ, Sheth PM, Kaul R, Loutfy MR. “Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.” AIDS. 2012 Jan 14;26(2):167-74.

Donahue DA, Kuhl BD, Sloan RD, Wainberg MA. “The viral protein Tat can inhibit the establishment of HIV-1 latency.” J Virol. 2012 Mar;86(6):3253-63. [Epub 2012 Jan 11].

Forbes J, Alimenti A, Singer J, Brophy J, Bitnun A, Samson L, Money D, Lee T, Lapointe N, Read S. “A national review of vertical HIV transmission.” AIDS Mar 2012.

Ivanova EL, Hart TA, Wagner AC, Aljassem K, Loutfy MR. “Correlates of anxiety in women living with HIV of reproductive age.” AIDS Behav. 2012 Jan 13. [Epub ahead of print].

Janbazian L, Price DA, Canderan G, Filali-Mouhim A, Asher TE, Ambrozak DR, Scheinberg P, Boulassel MR, Routy JP, Koup RA, Douek DC, Sekaly RP, Trautmann L. “Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation.” J Immunol. 2012 Feb 1;188(3):1156-67.

Loutfy MRMargolese SMoney DMGysler MHamilton SYudin MH. “Canadian HIV Pregnancy Planning Guidelines.” J Obstet Gynaecol Can. 2012 Jun;34(6):575-90.

Loutfy M, Raboud J, Wong J, Yudin M, Diong C, Blitz S, Margolese S, Hart T, Ogilvie G, Masinde K, Tharao W, Linklater G, Salam K, Ongoiba F, Angel J, Smaill F, Rachlis A, Ralph E, Walmsley S; Ontario HIV Fertility Research Team. “High prevalence of unintended pregnancies in HIV-positive women of reproductive age in Ontario, Canada: a retrospective study.” HIV Med. 2012 Feb;13(2):107-17. doi: 10.1111/j.1468-1293.2011.00946.x.

Martinez-Cajas JL, Wainberg MA, Oliveira M, Asahchop EL, Doualla-Bell F, Lisovsky I, Moisi D, Mendelson E, Grossman Z, Brenner BG. “The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.” J Antimicrob Chemother. 2012 Apr;67(4):988-94. Epub 2012 Feb 7.

Morfaw FL, Thabane L, Mbuagbaw LC, Nana PN. “Male participation in prevention programmes of mother to child transmission of HIV: A protocol for a systematic review to identify barriers, facilitators and reported interventions.” Systematic Reviews. 2012 1(1), 13.

Quashie PK, Mesplède T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. “Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir.” J Virol. 2012 Mar;86(5):2696-705.

Rourke SB, Gardner S, Burchell AN, Raboud J, Rueda S, Bayoumi AM, Loutfy M, Cooper C, Smieja M, Taylor D, Dipede T, Wobeser W, Major C, Waring V, Fisher M, Cairney J, Mittmann N, Salit IE, Crouzat F, Gough K, Ralph E, Sandre R, Kilby D, Rachlis A. “Cohort Profile: The Ontario HIV Treatment Network Cohort Study (OCS).” Int J Epidemiol. 2012 Feb 16. [Epub ahead of print].

Wacleche VS, Chomont N, Gosselin A, Monteiro P, Goupil M, Kared H, Tremblay C, Bernard N, Boulassel MR, Routy JP, Ancuta P. “The colocalization potential of HIV-specific CD8+ and CD4+ T-cells is mediated by integrin ?7 but not CCR6 and regulated by retinoic acid.” PLoS One. 2012;7(3):e32964. Epub 2012 Mar 28.

Wang C, McPherson AJ, Jones RB, Kawamura KS, Lin GH, Lang PA, Ambagala T, Pellegrini M, Calzascia T, Aidarus N, Elford AR, Yue FY, Kremmer E, Kovacs CM, Benko E, Tremblay C, Routy JP, Bernard NF, Ostrowski MA, Ohashi PS, Watts TH.“Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection.” J Exp Med. 2012 Jan 16;209(1):77-91.

Wainberg MA, Brenner BG. “The impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs.” Mol Biol Int. 2012, 256982-256982.

 

Research Publications 2011

Articles on CTN Studies

January 1, 2011 – December 31, 2011

Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, Lima VD, Montaner JS, Rourke SB, Smieja M, Tsoukas C, Hogg RS; CANOC Collaboration. “Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.”HIV Med. 2011 Jul;12(6):352-60. doi: 10.1111/j.1468-1293.2010.00890.x.

Cooper C, Thorne A; Canadian HIV Trials Network (CTN) Influenza Vaccine Research Group. “Vitamin D supplementation does not increase immunogenicity of seasonal influenza vaccine in HIV-infected adults.” HIV Clin Trials. 2011 Sep-Oct;12(5): 275-6.

Cooper C, Thorne A, Klein M, Conway B, Boivin G, Haase D, Shafran S, Zubyk W, Singer J, Halperin S, Walmsley S, on behalf of the CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. “Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults.” PLoS One 2011 Mar 25;6(3):e17758. PMID: 21555741. 

Cooper C, Thorne A; on behalf of the Canadian Institutes of Health Research-Canadian HIV Trials Network (CTN) Influenza Vaccine Research Group. “Influenza vaccine oculorespiratory syndrome incidence is reduced in HIV.” Vaccine. 2011 Aug 26. [Epub ahead of print]

Holodniy M, Brown ST, Cameron W, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK, Anis A, Goodall R, Hudson F, Paseczny M, Russo J, Schechter M, Deyton L, Darbyshire J. “Results of anitretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.” PLoS ONE. March 2011, 6(3): e14764.

Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Côté P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, Bernard N; for the Canadian cohort of HIV infected slow progressors. “Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.” J Virol. 2011 Jun;85(12):5949-5960. Epub 2011 Apr 6.

Mbuagbaw L, Thabane L, Ongolo-Zogo P, Lang T. “The challenges and opportunities of conducting a clinical trial in a low resource setting: the case of the Cameroon mobile phone SMS (CAMPS) trial, an investigator initiated trial.” Trials. 2011 Jun 9;12(1):145. [Epub ahead of print]

Nosyk B, Sharif B, Sun H, Cooper C, Anis AH; CIHR Canadian HIV Trials Network Influenza Vaccine Research Group. “The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus.” PLoS One. 2011;6(12):e27059. Epub 2011 Dec 6. 

Peters L, Neuhaus J, Mocroft A, Soriano V, Rockstroh J, Dore G, Puoti M, Tedaldi E, Clotet B, Kupfer B, Lundgren D, Klein MB, SMART Study Group. “Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis coinfected persons interrupting antiretroviral therapy in the SMART Study.” Antivir Ther. 2011;16(5):667-75.

Tan D, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke S, Tsoukas C, Loutfy MR, The Canoc Collaboration. “Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naïve HIV-infected patients initiating therapy.” J Acquir Immune Defic Syndr. 2011 Jun 24. [Epub ahead of print] PMID: 21709570 

Articles by CTN Investigators

January 1, 2011 – December 31, 2011

Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, Napravnik S, Rachlis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, Horberg M, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange SJ; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS. “Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in North America.” Am J Epidemiol. 2011 Sep 15;174(6):727-35. Epub 2011 Aug 3.

Andany N, Raboud JM, Walmsley S, Diong C, Rourke SB, Rueda S, Rachlis A, Wobeser W, Macarthur RD, Binder L, Rosenes R, Loutfy MR. “Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada.” HIV Clin Trials. 2011 Mar-Apr;12(2):89-103.

Antoniou T, Zagorski B, Loutfy MR, Strike C, Glazier RH. “Validation of case-finding algorithms derived from administrative data for identifying adults living with human immunodeficiency virus infection.” PLoS One. 2011;6(6):e21748. Epub 2011 Jun 30.

Asahchop EL, Oliveira M, Wainberg MA, Brenner BG, Moisi D, Toni T, Tremblay CL.“Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.” Antimicrob Agents Chemother. 2011 Feb; 55(2): 600-7.

Barnett PG, Chow A, Joyce V, Bayoumi AM, Griffin SC, Nosyk B, Sun H, Holodniy M, Brown ST, Sculpher M, Anis AH, Owens DK. “Determinants of the cost of health services used by patients with HIV.” Med Care 2011; 49(9): 848-856

Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA, Roger M. “Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors.” J Med Virol. 2011 Feb 25. doi: 10.1002/jmv.22047. [Epub ahead of print].

Church D, Gregson D, Lloyd T, Klein M, Beckthold B, Laupland K, Gill MJ. “Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections.” J Clin Microbiol. 2011 Jan; 49(1): 118-24. Epub 2010 Nov 17.

Cooper C, Kanters S, Klein M, Chaudhury P, Marotta P, Wong P, Kneteman N, Mills EJ.“Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort.” AIDS. 2011 Mar 27;25(6):777-86.

Crawley AM, Angel JB. “Expression of y-chain cytokine receptors on CD8(+) T cells in HIV infection with a focus on IL-7R? (CD127).” Immunol Cell Biol. 2011 Aug 23. doi: 10.1038/icb.2011.66. [Epub ahead of print]

DA, Altfeld M, Richman D, Connick E. “Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.” J Infect Dis. 2011 Feb 15; 203 (4): 442-51. Epub 2011 Jan 18.

de Pokomandy A, Rouleau D, Ghattas G, Trottier H, Vézina S, Coté P, Macleod J, Allaire G, Hadjeres R, Franco EL, Coutlée F. “HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV.”Clin Infect Dis. 2011 Mar 1. [Epub ahead of print].

Dhalla S, Poole G, Singer J, Patrick D, Kerr T. “Cognitive factors and willingness to participate in an HIV vaccine trial among HIV-positive injection drug users.” Psychol Health Med 2012.

Du Mont J, Macdonald S, Myhr T, Loutfy MR. “Sustainability of an HIV PEP Program for sexual assault survivors: ‘Lessons learned’ from health care providers.” Open AIDS J. 2011;5:102-12. Epub 2011 Nov 30.

García F, Routy JP. “Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1.” Vaccine. 2011 Sep 2;29(38):6454-63. Epub 2011 Jul 23.

Hecht FM, Wellman R, Busch MP, Pilcher CD, Norris PJ, Margolick JB, Collier AC, Little SJ, Markowitz M, Routy JP, Holte S; Acute Infection Early Disease Research Program. “Identifying the early post-HIV antibody seroconversion period.” J Infect Dis. 2011 Aug 15;204(4):526-33.

Holodniy M, Brown ST, Cameron W, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK, Anis A, Goodall R, Hudson F, Paseczny M, Russo J, Schechter M, Deyton L, Darbyshire J. “Results of anitretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.” PLoS ONE. March 2011, 6(3): e14764.

Joyce VR, Barnett PG, Chow A, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Kyriakides TC, Cameron DW, Youle M, Sculpher M, Anis AH, Owens DK. “Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: A randomized, controlled trial.” Med Decis Making.2011 Mar 7. [Epub ahead of print].

Keynan Y, Juno J, Kasper K, Rubinstein E, Fowke KR. “Targeting the chemokine receptor CCR5: good for HIV, what about other viruses?” J Infect Dis. 2011 Jan 15; 203(2): 292; author reply 293.

Krentz HB, Worthington H, Gill MJ. “Adverse health effects for individuals who move between HIV care centres.” J Acquir Immune Defic Syndr. 2011 Feb 21. [Epub ahead of print].

Lorenc T, Marrero-Guillamón I, Llewellyn A, Aggleton P, Cooper C, Lehmann A, Lindsay C. “HIV testing among men who have sex with men (MSM): systematic review of qualitative evidence.” Health Educ Res. 2011 Oct;26(5):834-46. Epub 2011 Aug 26.

Loutfy MR, Brunetta J, Kovacs C, Diong C, Gamble M, Antoniou T, Smith G, Halpenny R, Rosenes R, Raboud JM. “Four-year follow-up of polyalkylimide gel use for the treatment of HIV-associated lipoatrophy.” HIV Clin Trials. 2011 Nov-Dec;12(6):323-32.

Marshall BD, Wood E, Shoveller JA, Buxton JA, Montaner JS, Kerr T. “Individual, social, and environmental factors associated with initiating methamphetamine injection: implications for drug use and HIV prevention strategies.” Prev Sci. 2011 Jun;12(2):173-80.

McVey M, Cameron W, MacPherson P. “When infections collide–gummatous syphilis in an HIV-infected individual.” Int J Infect Dis. 2010 Sep;14 Suppl 3:e283-6. Epub 2010 Mar 24.

Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, Hecht R, Daar ES, Collier AC, Margolick J, Kilby JM, Routy JP, Conway B, Kaldor J, Levy J, Schooley R, Cooper DA, Altfeld M, Richman D, Connick E. “Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.” J Infect Dis. 2011 Feb 15; 203 (4): 442-51. Epub 2011 Jan 18.

Mohamed AA, Loutfy SA, Craik JD, Hashem AG, Siam I. “Chronic hepatitis C genotype-4 infection: role of insulin resistance in hepatocellular carcinoma.” Virol J. 2011 Nov 1;8:496.

Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K; ECHO study group.“Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.” Lancet. 2011 Jul 16;378(9787):238-46.

Monteiro P, Gosselin A, Wacleche VS, El-Far M, Said EA, Kared H, Grandvaux N, Boulassel MR, Routy JP, Ancuta P. “Memory CCR6+CD4+ T cells are preferential targets for productive HIV type 1 infection regardless of their expression of integrin {beta}7.” J Immunol. 2011 Mar 11. [Epub ahead of print].

Newmeyer T, Tecimer SN, Jaworsky D, Chihrin S, Gough K, Rachlis A, Martin J, Mohammed S, Loutfy MR. “Case series of fertility treatment in HIV-discordant couples (male positive, female negative): the Ontario experience.” PLoS One. 2011;6(9):e24853. Epub 2011 Sep 28.

Poon AF, McGovern RA, Mo T, Knapp DJ, Brenner B, Routy JP, Wainberg MA, Harrigan PR. “Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data.” AIDS. 2011 Oct 23;25(16):2019-26.

Sloan RD, Kuhl BD, Donahue DA, Roland A, Bar-Magen T, Wainberg MA. “Transcription of preintegrated HIV-1 cDNA modulates cell surface expression of MHC-I via Nef.”Journal of Virology. 2011 Jan 5. [Epub ahead of print].

Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). “Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening.” J Infect Dis. 2011 Sep;204(6):893-901.

Tan DHS, Kaul R, Raboud J, Walmsley S. “No impact of oral tenofovir disoproxil fumarate on herpes simplex virus type 2 shedding in HIV-infected adults.” AIDS. 2011; 25: 207-210.

Tremblay CTrottier BRachlis ABaril JGLoutfy MLalonde RSampalis JS,Boulerice F. “Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.” HIV Clin Trials. 2011 May-Jun;12(3):151-60.

van Grevenynghe J, Cubas RA, Noto A, Dafonseca S, He Z, Peretz Y, Filali-Mouhim A, Dupuy FP, Procopio FA, Chomont N, Balderas RS, Said EA, Boulassel MR, Tremblay CL, Routy JP, Sékaly RP, Haddad EK. “Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis.” J Clin Invest. 2011 Oct 3;121(10):3877-3888. doi: 10.1172/JCI59211. Epub 2011 Sep 19.

Wainberg MA, Brenner BG. “Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.” Viruses. 2010 Nov;2(11):2493-508. Epub 2010 Nov 11.

Young CD, Angel JB. “HIV infection of thymocytes inhibits IL-7 activity without altering CD127 expression.” Retrovirology. 2011 Sep 16;8:72.

Yudin MH, Loutfy M. “Advocating for assistance with pregnancy planning in HIV-positive individuals and couples: an idea whose time has come.” J Obstet Gynaecol Can. 2011 Mar;33(3):269-71.

Xu HT, Asahchop EL, Oliveira M, Quashie PK, Quan Y, Brenner BG, Wainberg MA.“Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations.” J Virol. 2011 Nov;85(21):11300-8. Epub 2011 Aug 17.

Research Publications 2010

Articles on CTN Studies

January 1, 2010 – December 31, 2010

Tan DH, Raboud JM, Kaul R, Grinsztejn B, Cahn P, Walmsley SL. “Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the Valacyclovir in delaying antiretroviral treatment entry (VALIDATE) trial.” Trials. 2010 Nov 24; 11: 113.

Routy JP, Boulassel MR, Yassine-Diab B, Nicolette C, Healey D, Jain R, Landry C, Yegorov O, Tcherepanova I, Monesmith T, Finke L, Sékaly RP. “Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.” Clin Immunol. 2010 Feb; 134(2): 140-7.

Raboud JM, Loutfy MR, Su D, Bayoumi AM, Klein MB, Cooper C, Machouf N, Rourke S, Walmsley S, Rachlis A, Harrigan PR, Smieja M, Tsoukas C, Montaner JS, Hogg RS; CANOC Collaboration. “Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.” BMC Infect Dis. 2010 Feb 25; 10: 40.

Palmer A, Klein M, Raboud J, Cooper C, Hosein S, Loufty M, Machouf N, Montaner J, Rourke S, Smieja M, Tsoukas C, Yip B, Milan D, Hogg R, and the CANOC Collaboration. “Cohort profile: the Canadian Observational Cohort Collaboration.” Int. J. Epidemiol. Advanced access published Feb 15, 2010.

Potter M, Klein MB. “Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B.” HIV Therapy. 2009, 3: 189-207.

Kiberd MB, Cooper C, Slaunwhite JM, Halperin B, Haase D, McNeil SA. “Pandemic influenza is a strong motivator for participation in vaccine clinical trials among HIV-positive Canadian adults.” Can J Infect Dis Med Microbiol. 2009; 20(4): 124-129.

Fontaine J, Coutlée F, Tremblay C, Routy JP, Poudrier J, Roger M. “HIV Infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease.” J Infec Dis. 2009; 199 (1): 1007-1018.

Articles by CTN Investigators

January 1, 2010 – December 31, 2010

Althoff KN, Gebo KA, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Eron JJ, Napravnik S, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Deeks SG, Martin JN, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Goedert JJ, McKaig RG, Thorne J, Rachlis A, Moore RD, Justice AC; for the North American AIDS Cohort Collaboration on Research and Design. “CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?” AIDS Res Ther. 2010 Dec 15; 7(1): 45.

Asahchop EL, Oliveira M, Brenner BG, Martinez-Cajas JL, Toni T, Ntemgwa M, Moisi D, Dandache S, Stranix B, Tremblay CL, Wainberg MA. “Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes.”Antiviral Res. 2010 Sep; 87(3): 367-72. Epub 2010 Jun 10.

Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, Sun C, Wang S, Learn GH, Morgan CJ, Schumacher JE, Haynes BF, Keele BF, Hahn BH, Shaw GM.“Wide variation in the multiplicity of HIV-1 infection among injection drug users.” J Virol.2010 Apr 7.

Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA. “Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor.” J Virol. 2010 Sep; 84(18): 9210-6. Epub 2010 Jul 7.

Boucher JG, Parato KA, Frappier F, Fairman P, Busca A, Saxena M, Blahoianu MA, Ma W, Gajanayaka N, Parks RJ, Kumar A, Angel JB. “Disparate regulation of LPS-induced MAPK signaling and IL-12p40 expression between different myeloid cell types with and without HIV infection.” Viral Immunol. 2010 Feb; 23(1): 17-28.

Boulet S, Song R, Kamya P, Bruneau J, Shoukry NH, Tsoukas CM, Bernard NF. “HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells.” J Immunol. 2010 Feb 15; 184(4): 2057-64.

Cahn P, Wainberg MA. “Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.” J Antimicrob Chemother. 2010 Feb; 65(2): 213-7.

Ciccone EJ, Read SW, Mannon PJ, Yao MD, Hodge JN, Dewar R, Chairez CL, Proschan MA, Kovacs JA, Sereti I. “Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels.” Mucosal Immunol. 2010 Mar; 3(2): 172-81.

Cooper C. “Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success.” Can J Gastroenterol. 2010 Jun; 24(6): 385-90.

Cooper C, Mills E. “Successes in the HIV epidemic response in Africa: maintaining momentum in uncertain times.” Int J Infect Dis. 2010 Sep; 14 Suppl 3: e357-8.

Coutsinos D, Invernizzi CF, Xu H, Brenner BG, Wainberg MA. “Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1.” Antivir Chem Chemother. 2010 Jan 5; 20(3): 117-31.

d’Arminio Monforte A, González L, Haberl A, Sherr L, Ssanyu-Sseruma W, Walmsley SL; Women for Positive Action. “Better mind the gap: addressing the shortage of HIV-positive women in clinical trials.” AIDS. 2010 May 15; 24(8): 1091-4.

Donahue DA, Sloan RD, Kuhl BD, Bar-Magen T, Schader SM, Wainberg MA. “Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture.” Antimicrob Agents Chemother. 2010 Mar; 54(3): 1047-54.

Gosselin A, Monteiro P, Chomont N, Diaz-Griffero F, Said EA, Fonseca S, Wacleche V, El-Far M, Boulassel MR, Routy JP, Sekaly RP, Ancuta P. “Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection.” J Immunol. 2010 Feb 1; 184(3): 1604-16.

Iannello A, Samarani S, Debbeche O, Boulassel MR, Tremblay C, Toma E, Routy JP, Ahmad A. “Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study.” J Immunol. 2010 Jan 1; 184(1): 114-26.

Iannello A, Boulassel MR, Samarani S, Tremblay C, Toma E, Routy JP, Ahmad A. “HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication.” J Infect Dis. 2010 Feb 15; 201(4): 608-17.

Iannello A, Samarani S, Debbeche O, Boulassel MR, Tremblay C, Toma E, Routy JP, Ahmad A. “Potential role of IL-18 in the immunopathogenesis of AIDS, HIV-associated lipodystrophy and related clinical conditions.” Curr HIV Res. 2010 Mar 1; 8(2): 147-64.

Krentz HB, Gill J. “Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 ul.” AIDS. 2010 Nov 13; 24(17): 2750-3.

Krentz HB, Gill J. “Monitoring and adjusting for future needs in response to changing HIV policies.” Lancet Infect Dis. 2010 Oct; 10(10): 671-2.

Lalonde RG, Thomas R, Rachlis A, Gill MJ, Roger M, Angel JB, Smith G, Higgins N, Trottier B. “Successful implementation of a national HLA-B*5701 genetic testing service in Canada.” Tissue Antigens. 2010 Jan; 75(1): 12-8.

la Porte C, Voduc N, Zhang G, Seguin I, Tardiff D, Singhal N, Cameron DW. “Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects.” Clin Pharmacokinet. 2010 Jul 1; 49(7): 449-54. doi:  10.2165/11531820-000000000-00000.

Leece P, Kendall C, Touchie C, Pottie K, Angel JB, Jaffey J. “Cervical cancer screening among HIV-positive women. Retrospective cohort study from a tertiary care HIV clinic.”Can Fam Physician. 2010 Dec;56(12): e425-31.

McVey M, Cameron W, MacPherson P. “When infections collide–gummatous syphilis in an HIV-infected individual.” Int J Infect Dis. 2010 Sep;14 Suppl 3:e283-6. Epub 2010 Mar 24.

Mills E, Ford N, Nabiryo C, Cooper C, Montaner J. “Ensuring sustainable antiretroviral provision during economic crises.” AIDS. 2010.

Money D. “H1N1 in Pregnant Women: a Challenge Overlooked?” Journal of Obstetrics & Gynaecology. Invited Editorial. 2009 Nov. (In press).

Ndongala ML, Kamya P, Boulet S, Peretz Y, Rouleau D, Tremblay C, Leblanc R, Côté P, Baril JG, Thomas R, Vézina S, Boulassel MR, Routy JP, Sékaly RP, Bernard NF.“Changes in function of HIV-specific T-cell responses with increasing time from infection.”Viral Immunol. 2010 Apr; 23(2): 159-68.

O’Bryan T, Jadavji T, Kim J, Gill MJ. “An avoidable transmission of HIV from mother to child.” CMAJ. 2010 Nov 22. [Epub ahead of print].

Raboud J, Li M, Walmsley S, Cooper C, Blitz S, Bayoumi AM, Rourke S, Rueda S, Rachlis A, Mittmann N, Smieja M, Collins E, Loutfy MR. “Once daily dosing improves adherence to antiretroviral therapy.” AIDS Behav. 2010 Sep 28. [Epub ahead of print].

Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, Hill BJ, Noto A, Ancuta P, Peretz Y, Fonseca SG, Van Grevenynghe J, Boulassel MR, Bruneau J, Shoukry NH, Routy JP, Douek DC, Haddad EK, Sekaly RP. “Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.” Nat Med. 2010 Apr; 16(4): 452-9

Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. “Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.” Clin Infect Dis.2010 Feb 15; 50(4): 605-12.

Presentations

January 1, 2010 – May 16, 2010

17th Conference on Retroviruses and Opportunistic Infections (CROI), February 16-19, 2010, San Francisco, CA

Cooper C, Thorne A, Walmsley S, Conway B, Kilby D, Klein M, Haase D, Cohen J, Shafran S, Singer J, and the Canadian HIV Trials Network Influenza Vaccine Res Group. “A controlled trial to compare the immunogenicity and efficacy of 3 seasonal influenza vaccine dosing strategies in HIV-infected adults.” Poster 161.

Coutsinos D, Invernizzi C, Spira B, Brenner B, Wainberg M. “Template-dependent mechanisms involved in K65R drug resistance development in subtype B and C HIV-1.” Poster 548.

Donahue D, Sloan R, Kuhl B, Bar-Magen T, Schader S, Wainberg M. “Stage-dependent inhibition of HIV-1 in vitro and implications for raltegravir.” Poster 262.

Hull M, Loutfy M, Zhang W, Shen A, Druyts E, Klein M, Machouf N, Rachlis A, Montaner J, Hogg R, and the Canadian Observational Cohort Collaboration. “Persistent low-level viremia is associated with increased risk of virologic failure and mortality.” Poster 504.

Iannello A, Boulassel MR, Tremblay C, Toma E, Routy JP, Ahmad A. “Dynamics of IL-21 production in the course of HIV-1 infection: consequences for the survival of CD4+ T Cells.” Poster 386.

Kamya P, Boulet S, Song R, Bruneau J, Shoukry N, Kovacs C, Sekaly PR, Tsoukas C, Tremblay C, Bernard N, and Canadian Cohort of HIV Infected Slow Progressors. “NK receptor-HLA ligand requirements for increased polyfunctional potential in NK cells from individuals carrying KIR3DL1*h/*y+ HLA-B*57.” Oral abstracts 452.

Routy JP, Tremblay C, Angel J, Rouleau D, Trottier B, Baril JG, Trottier A, Montaner J, Singer J, Boulassel MR. “Effect of valproic acid to purge HIV reservoir: a multicenter randomized clinical trial.” Poster 496.

Sharif B, Sun H, Nosyk B, Thorne A, Zubyk W, Cooper C, Anis A, and the Canadian HIV Trials Network Influenza Vaccine Res Group. “Cost effectiveness of influenza vaccination among HIV+ patients receiving ART.” Poster 811.

19th Annual Canadian Conference on HIV/AIDS Research, 13-16 May 2010, Saskatoon

Adams A, Rouleau D, Cox J, Saeed S, Klein M, for the Canadian Co-infection Cohort.“Poor quality of life in HIV-Hepatitis C Virus (HCV) Co-infection is predominately a consequence of unfavourable social conditions.” Poster 134.

Appuzo L, Langan S, Imteyaz H, Gallant J, Barditch-Crovo P, Singer J, Tossonian HK, Ranjbaran F, Conway B, Margolick J. “Incidence of sexually transmitted diseases in recent HIV-seroconverters.” Poster 131.

Balfour L, Macpherson P, Corace K, Tasca GA, Angel J, Gaber G, Cameron W. “Optimizing HIV treatment adherence by assessing HIV medication readiness and by preparing patients for treatment.” Poster 125.

Balfour L, Sandre D, Corace K, Al-Dabbagh R, Tasca GA, Pipe A, Reid R, Aitken D, la Porte C, Giguere P, Angel J, Garber G, Lee C, Cooper C, Cameron W, Macpherson P.“Preliminary data on the HIV quit smoking pilot study.” Poster 166.

Conway B, Appuzo L, Singer J, Ranjbaran F, Fraser C, Kasper K, Loufty M, Rachlis A, Langan S, Margolick J. “Screening of patients with acute/early HIV infection to consider randomization to immediate antiretroviral therapy (ART) versus observation.” Oral O011.

Cooper C, Thorne A, Klein M, Conway B, Kilby D, Haase, Cohen J, Shafran S, Singer J, Walmsley S. “Immunogenicity of three seasonal influenza vaccine dosing strategies in HIV-infected adults.” Oral O032.

Cooper C, Mackie D. “A survey of HIV-HCV co-infection research conducted by service providers in Ontario.” Poster 202.

Diong C, Raboud J, Cooper C. “Hepatitis C virus co-infection diminishes the likelihood of antiretroviral-induced hyperlipidemia.” Oral O034.

Fairman, PJ, Angel JB. “Effects of HIV-1 on dendritic cell mutation.” Poster 115.

Klein M, Thorpe J, Saeed S, Cohen J, Conway B, Cooper C, Côté P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. “A portrait of HIV-Hepatitis C co-infected persons in care in Canada: The Canadian Co-Infection Cohort Study (CCC; CTN 222).” Poster 135.

Laporte C, et al. “Drug interactions between voriconazole, darunavir/r and etravirine in an HIV-infected patient.” Abstract 7287.

Lebouche B, Levy JJ, Lemieux R, Wallach I, Gilmore N, Routy JP. “Ethical issues surrounding HIV management in older individuals.” Oral O101.

Lebouche B, Tremblay P, Quesnel M, Garnier C, Gilmore N, Boulassel M-R, Routy JP. “Participants’ perceptions and representations after dendritic cell immunotherapy and HAART discontinuation in the CTN 239 study.” Poster 221.

Loufty M, Laporte C, Walmsley S, Tseng A, Mohammed S, Li M, Klein M, Angel J, Conway B, Burdge D, Rachlis A, Gough K, Cohen J, Smaill F, Haase D, Loemba H, Trottier S, de Pokemandy A, Blitz S, Raboud J for PK in Women Study Team. “Antiretroviral pharmacokinetics in HIV-positive women with full virologic suppression on current regimens.” Poster 153.

Money D, Raboud J, Venables L, Blitz S, Krajden M, van Schalkwyk J, Mcalpine J, Walmsley A, Canadian Women’s HIV/HPV Study Group, Coutlee F. “Patterns of HPV infection among a cohort of HIV positive women.” Oral O033.
Pai NP, Kurji J, Singam A, Barick R, PV Shivkumar PV, Klein M, Chhabra S. “CIHR CTN I S243 study: Simultaneous timed triple screening (SITTS) for HIV, hepatitis B, and syphilis with rapid point-of-care tests in rural pregnant women in India.” Oral O037.

Raboud J, Mcapline J, Blitz S, Venables L, Singer J, Castillo E, Loufty M, Smaill F, Walmsley S, A Canadian Women’s HPV/AIV Study Group, Money D. “Cervical dysplasia associated with presence and number of HPV types among a cohort of HIV positive women.” Oral O038.

Rouleau D, Fotin C, Trottier B, Lalonde R, Cote P, Routy JP, Matte MF, Tsarevsky I, Baril JG. “ ‘A collaborative work: Le guide de thérapie antirétrovirale pour professionnels du Québec.’ Recommendations for first line therapy.” Poster 141.

Routy JP, Tremblay C, Angel J, Rouleau D, Trottier B, Baril JG, Trottier S, Montaner J, Bichel D, Singer J and Boulassel MR. “Valproic acid to reduce HIV from resting CD4+ memory cells: Results from a Canadian multicentre randomized clinical trial (CTN 205).”?Oral O060.

Tan, D, Raboud JM, Walmsley S. “Shedding of herpes simplex virus in HIV-1-infected individuals receiving suppressive antiretroviral therapy.” Oral O036.

Tcherepanova I, Boulassel MR, Carreno A, Carpenter H, Loutfy M, Vezina S, Tremblay C, Angel J, Gill J, Baril J, Smaill F, Jain R, Healey D, Chew T, Nicolette C, and Routy JP. “AGS-004, an autologous dendritic cell therapy impacts on the evolution of residual HIV virus along with a substantial increase in time to viral rebound, during an STI in the CTN 239 clinical study.” Oral O062.

Thorpe J, Saeed S, Moodie E, Klein M, for the Canadian Co-infection Cohort Study (CTN222). “Interruption of antiretroviral therapy (ART) is associated with progression of liver fibrosis in HIV/HCV co-infected adults.” Oral O014.

Tremblay C, Trottier B, Rachlis A, Baril J-G, Loufty M, Lalonde R, Sampalis J, Boulerice F. “Durability of treatment with Atazanvir/Ritonavir-based HAART regimen in treatment-naïve HIV patients.” Poster 139.

XVIII International AIDS Conference, 18-23 July 2010, Vienna

Routy JP. “HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to pre-ART viral load) and delay in the time to viral rebound during a 12 week STI.”

Research Publications 2009

Articles on CTN studies

January 1, 2009 – December 31, 2009

Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodiny M, Cameron DW, Brown ST; OPTIMA Team 1. “Quality of life of patients with advance HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.” J Acquir Immune Defic Syndr. 2009 Aug 15; 51(5): 631-9. 

Apuzzo LG, Vaida F, Gallant JE, Ernstrom KB, Little SJ, Routy JP, Collier AC, Conway B, Markowitz MH, Hecht FM, Walker BD, Connick E, Margolick JB. “Tolerability and efficacy of PI versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.” J Acquir Immune Defic Syndr. 2009 Mar; 5(3): 267-275. 

Harris M, Côté H, Ochoa C, Allavena C, Negredo E, Thorne A, Cahn P, Zala C, Raffi F, Clotet B, Singer J, Montaner J; CTN 177 Study Team. “A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naïve HIV-infected patients.” J Acquir Immune Defic Syndr. 2009 Mar 1; 50(3): 335-337.

Klein MB, Saeed S, Yang H, Cohen J, Conway B, Cooper C, Cote P, Cox J, Gill J, Haase D, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. “Cohort profile: The Canadian HIV-Hepatitis C Co-Infection Cohort Study.”Int J Epidemiol. 2009 Sep 28.

Moodie EEM, Pai NP, Klein MB. “Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts.” PLoS ONE 2009; 4(2):e4517.

Moscroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M for the INSIGHT SMART study group. “Interruption of antiretroviral therapy is associated with increased plasma cystain C.” AIDS 2009; 23:71-82.

Articles by CTN Investigators

January 1, 2009 – December 31, 2009

Angel JB, Greaves W, Long J, Ward D, Rodriguez AE, Scevola D, DeJesus E.“Virologic and immunologic activity of PegIntron in HIV disease.” AIDS. 2009 Nov 27; 23(18): 2431-8.

Antiretroviral Therapy Cohort Collaboration. “Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.” Int J Epidemiol. 2009 Dec; 38(6): 1624-33.

Antoniou T, Raboud JM, Kovacs C, Diong C, Brunetta J, Smith G, Halpenny R, Beninger F, Loutfy MR. “Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy.” AIDS Care. 2009 Oct; 21(10): 1247-52.

Breton G, Yassine-Diab B, Cohn L, Boulassel MR, Routy JP, Sékaly RP, Steinman RM.“siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals.” J Clin Immunol. 2009 Sep; 29(5): 637-45.

Bogoch I, Walmsley S. “First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach.” Curr Opin HIV AIDS. 2009 Nov; 4(6): 493-8. Review.

Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sékaly RP. “HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.” Nat Med. 2009 Aug; 15(8): 893-900.

Cohen J. “HIV/AIDS research. Surprising AIDS vaccine success praised and pondered.”Science. 2009 Oct 2; 326(5949): 26-7.

Cohen J. “AIDS vaccine research. HIV natural resistance field finally overcomes resistance.” Science. 2009 Dec 11; 326(5959): 1476-7.

de Pokomandy A, Rouleau D, Ghattas G, Vézina S, Coté P, Macleod J, Allaire G, Franco EL, Coutlée F, HIPVIRG Study Group. “Prevalence, clearance, an incidence of anal human papillomavirus infection in HIV-infected men: The HIPVIRG cohort study.” J Infect Dis. 2009 April 1; 199(7): 965-973.

Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Kushel MB, Goedert JJ, McKaig RG, Moore RD. “Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.” Clin Infect Dis. 2009 Nov 15; 49(10): 1582-90.

Faucher S, Crawley AM, Decker W, Sherring A, Bogdanovic D, Ding T, Bergeron M, Angel JB, Sandstrom P. “Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma.” PLoS One. 2009 Aug 19; 4(8): e6690.

Fontaine J, Coutlée F, Tremblay C, Routy JP, Poudrier J, Roger M; Montreal Primary HIV Infection and Long?Term Nonprogressor Study Groups. “HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease.” J Infect Dis. 2009 Feb 20. [Epub ahead of print].

Frederick T, Burian P, Terrault N, Cohen M, Augenbraun M, Young M, Seaberg E, Justman J, Levine AM, Mack WJ, Kovacs A. “Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women’s Interagency HIV Study (WIHS).” AIDS Patient Care STDS. 2009 Nov; 23(11): 915-23.

Gathe J, Silva BA, Cohen DE, Loutfy MR, Podzamczer D, Rubio R, Gibbs S, Marsh T, Naylor C, Fredrick L, Bernstein B. “A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naïve subjects through 48 weeks.” J Acquir Immune Defic Syndr. 2009 Feb 16. [Epub ahead of print].

Grennan T, Walmsley S. “Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class.” J Int Assoc Physicians AIDS Care(Chic Ill). 2009 Nov-Dec; 8(6): 354-63. Epub 2009 Oct 23. Review.

Huang KH, Loutfy MR, Boulet S, Toma E, Tsoukas CM, Bernard NF. “Predictive value of immune parameters before treatment interruption (TI) for CD4+ T-cell count change during TI in HIV infection.” Antivir Ther. 2009; 14(3): 381-92.

Hull MW, Harris M, Lima V, Guillemi S, Harrigan PR, Montaner JS. “Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.”J Clin Pharmacol. 2009 Feb; 49(2): 155-61.

Hull MW, Lima VD, Hogg RS, Harrigan PR, Montaner JS. “Epidemiology of treatment failure: a focus on recent trends.” Curr Opin HIV AIDS. 2009 Nov; 4(6): 467-73.

Iannello A, Samarani S, Debbeche O, Ahmad R, Boulassel MR, Tremblay C, Toma E, Routy JP, Ahmad A. “Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells.” J Virol. 2009 Jun; 83(12): 5999-6010.

Iannello A, Samarani S, Debbeche O, Tremblay C, Toma E, Boulassel MR, Routy JP, Ahmad A. “Role of interleukin-18 in the development and pathogenesis of AIDS.” AIDS Rev. 2009 Jul-Sept; 11(3): 115-25.

INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. “Interleukin-2 therapy in patients with HIV infection.” N Engl J Med. 2009 Oct 15; 361(16): 1548-59.

Jürgens R, Cohen J, Cameron E, Burris S, Clayton M, Elliott R, Pearshouse R, Gathumbi A, Cupido D. “Ten reasons to oppose the criminalization of HIV exposure or transmission.” Reprod Health Matters. 2009 Nov; 17(34): 163-72.

Jones RB, Yue FY, Gu XX, Hunter DV, Mujib S, Gyenes G, Mason RD, Mohamed MR, MacDonald KS, Kovacs C, Ostrowski MA. “Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations.” J Virol. 2009 Sep; 83(17): 8722-32.

Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, Schechter M, Peeters M, Picchio G, Vingerhoets J, Woodfall B, De Smedt G; DUET-1, DUET-2 study groups. “Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.” AIDS. 2009 Nov 13; 23(17): 2289-300.

Kiberd MB, Cooper C, Slaunwhite JM, Halperin B, Haase D, McNeil SA. “Pandemic influenza is a strong motivator for participation in vaccine clinical trials among HIV-positive Canadian adults.” Can J Infect Dis Med Microbiol. 2009; 20(4): 124-129.

Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD; NA-ACCORD Investigators. “Effect of early versus deferred antiretroviral therapy for HIV on survival.” N Engl J Med. 2009 Apr 30; 360(18): 1815-26.

Lee PI, Ciccone EJ, Read SW, Asher A, Pitts R, Douek DC, Brenchley JM, Sereti I.“Evidence for translocation of microbial products in patients with idiopathic CD4 lymphocytopenia.” J Infect Dis. 2009 Jun 1; 199(11): 1664-70.

Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, Montaner J. “The combined effect of modern highly active antiretroviral therapy regimens and adherance on mortality over time.” J Acquir Immune Defic Syndr. 2009 Feb 13. [Epub ahead of print]

Lima V, Harrigan R, Montaner J. “Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the pagman assay in comparison to the amplicor assay.” J Acquir Immune Defic Syndr. 2009 Feb 25. [Epub ahead of print]

Loutfy MR, Hart TA, Mohammed SS, Su D, Ralph ED, Walmsley SL, Soje LC, Muchenje M, Rachlis AR, Smaill FM, Angel JB, Raboud JM, Silverman MS, Tharao WE, Gough K, Yudin MH; Ontario HIV Fertility Research Team. “Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study.” PLoS One. 2009 Dec 7; 4(12): e7925.

Ma W, Mishra S, Gajanayaka N, Angel JB, Kumar A. “HIV-1 nef inhibits lipopolsaccharide-induced IL-12p40 expression by inhibiting JNK-activated NFkappa B in human monocytic cells.” J Biol Chem. 2009 Mar 20; 284(12): 7578-75.

Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H; Protocol 004 Part II Study Team. “Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.” J Acquir Immune Defic Syndr. 2009 Nov 1; 52(3): 350-6.

Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. “Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).” J Int AIDS Soc. 2009 Jun 30; 12(1): 11.

Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J; TRIAD Study Group.“Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.” J Antimicrob Chemother. 2009 Aug; 64(2): 398-410. Epub 2009 Jun 10.

Money D. “H1N1 in pregnant women: A challenge overlooked?” J Obstet Gynaecol Can. Invited Editorial. 2009 Nov.

Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA; Antiretroviral Therapy Cohort Collaboration. “Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.” J Acquir Immune Defic Syndr. 2009 Nov 1; 52(3): 357-63.

Moscroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M for the INSIGHT SMART study group. “Interruption of antiretroviral therapy is associated with increased plasma cystain C.” AIDS 2009; 23: 71-82.

Ndongala ML, Perestz Y, Boulet S, Doroudchi M, Yassine-Diab B, Boulassel MR, Rouleau D, Tremblay C, Leblanc R, Routy JP, Sékaly RP, Bernard NF. “HIV Gag p24 specific responses secreting IFN-gamma and/or IL-2 in treatment-naïve individuals in acute infection early disease (AIED) are associated with low viral load.” Clin Immunol.2009 Jan 7.

Nosyk B, Sun H, Bansback N, Guh DP, Li X, Barnett P, Bayoumi A, Griffin S, Joyce V, Holodiny M, Owens DK, Anis AH. “The concurrent validity and responsiveness of the health utilities (HUI 3) among patients with advanced HIV/AIDS.” Qual Life Res. 2009 Sept; 18(7): 815-24.

Pai NP, Joshi R, Moodie EE, Taksande B, Kalantri SP, Pai M, Tulsky JP, Reingold A.“Profile of adults seeking voluntary HIV testing and counseling in rural Central India: results from a hospital-based study”. AIDS Care 2009 March; 21(3): 294 300.

Pai NP, Klein MB. “Rapid testing at labor and delivery to prevent mother-to-child HIV transmission in developing settings: issues and challenges.” Women’s Health 2009; 5(1), 55-62.

Perreault M, Mousseau M, Laurier C, Rabouin D, Desbiens S, Côté P, Rouleau D, Lahaie C, Charron MA, Carbonneau MJ. “Treatment of HIV marginalized patients: an approach to documenting medical and psychosocial appointments of patients with problematic drug use.” Can J Public Health. 2009 Nov-Dec; 100(6): 459-62.

Potter M, Klein MB. “Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B.” HIV Therapy. 2009, 3: 189-207.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group. “Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.” J Infect Dis. 2009 Sep 15; 200(6): 973-83.

Sheth PM, Kovacs C, Kemal KS, Jones RB, Raboud JM, Pilon R, la Porte C, Ostrowski M, Loutfy M, Burger H, Weiser B, Kaul R; Toronto Mucosal Immunology Group.“Persistent HIV RNA shedding in semen despite effective antiretroviral therapy.” AIDS.2009 Sep 24; 23(15): 2050-4.

Sturtevant D, Preiksaitis J, Singh A, Houston S, Gill J, Predy G, Fisher D, Senthilselvan A, Manfreda J, Boffa J, Long R. “The feasibility of using an ‘opt-out’ approach to achieve universal HIV testing of tuberculosis patients in Alberta.” Can J Public Health. 2009 Mar-Apr; 100(2): 116-20.

Tan D, Asztalos E, Douglas D, Read S, Bitnun A. “Congenital transmission of human immunodeficiency virus, cytomegalovirus, and toxoplasmosis in a premature infant.”Pediatr Infect Dis J. 2009 Dec; 28(12): 1129-31.

Tan D, Kaul R, Walmsley S.  “Left out but not forgotten: Should closer attention be paid to co-infection with herpes simplex virus type 1 and HIV?” Can J Infect Dis Med Microbiol.2009; 20: e1-e7.

Tcherepanova I, Starr A, Lackford B, Adams MD, Routy JP, Boulassel MR, Calderhead D, Healey D, Nicolette C. “The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.” PLoS One. 2009 Jun 10; 4(6): e5853.

Wainberg MA.New findings on blockage of HIV-1 RNase H activity.” AIDS. 2009 Jan 14;23(2): 223-4.

Wainberg MA, Martinez-Cajas JL. “Sequencing of therapy to avoid resistance and the need for new antiretroviral drugs in the treatment of HIV disease.” Infect Disord Drug Targets. 2009 Apr; 9(2): 172-90. Review.

Walmsley SL, Squires K, Weiss L, Easterbrook P, Orani A, Kraft M, Scherer J.“Multidrug-experienced HIV-1 infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men”. AIDS. 2009 Jan 28; 23(3): 429-31.

When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR. “Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.” Lancet. 2009 Apr 18; 373(9672): 1352-63.

Zuniga JM, Whiteside A, Ghaziani A, Bartlett JG (editors). “A decade of HAART–the development and global impact of highly active antiretroviral therapy.” Eur J Public Health. 2009 Mar 5. 

Presentations

January 1, 2009 – April 1, 2009

16th Conference on Retroviruses and Opportunistic Infections (CROI) February 8-11, 2009, Montréal

Duprez D, and INSIGHT/SMART Group. “High-density lipoprotein particles but not low-density lipoprotein particles predict cardiovascular disease events in HIV patients: strategies for management of ART study.” Oral abstract 149.

Levy Y, and the SILCAAT Science Committee. “Effect of interleukin 2-on clinical outcomes in patients with CD4+ cell count 50 to 299/mm3: primary results of the SILCAAT study.” Oral abstract 90bLB.

Losso M, Abrams D, and INSIGHT ESPRIT Study Group. “Effect of interleukin 2-on clinical outcomes in patients with a CD4+ cell count of 300/mm3: primary results of the ESPRIT study.” Oral abstract 90Alb.

Baker J, Duprez D, Rapkin J, Grimm R, Neaton J, Henry K. “Untreated HIV infection is associated with impaired arterial elasticity.” Poster 725.

Rodger A, Fox Z, Lundgren J, Kuller L, Boesecke C, Gey D, Skoutelis A, Goetz M, Philips A, for the INSIGHT SMART study group. “Does activation of inflammatory and coagulation pathways independently predict the development of opportunistic disease in patients with HIV infection?” Poster 733.

Peters L, for the INSIGHT SMART study group. “Interruption of ART changes in hyaluronic acid as marker of liver fibrosis progression in strategies for management of ART viral hepatitis-co-infected participants and matched controls.” Poster 858.

Neuhaus J, Jacobs D, and the INSIGHT SMART, MESA, and CARDIA study groups.“Markers of inflammation, coagulation, and renal function in HIV-infected adults in the strategies for management of ART study and in 2 large population-based studies, coronary artery risk development in young adults and multi-ethnic study of atherosclerosis.” Poster 740.

18th Annual Canadian Conference on HIV/AIDS Research, Vancouver April 23-26, 2009. Canadian Association for HIV Research

Anis A, Sun H, Nosyk B, Guh D, Bansback N, Singer J, Holodniy M, Brown ST, Kyriakides T, Cameron DW. “Predicting death, AIDS and serious adverse events in the
OPTIMA trial.” Poster 135.

Feng DY, Goupil C, Mathieu J, Delisle M,Chiasson JC, Dagenais C, Gagné C, Swidzinski M, Boulassel MR for the CTN 239 investigators, Routy JP for the CTN-239 Study Investigators. ”A nursing perspective of apheresis procedures performed in HIV-infected subjects receiving a monocytes-derived dendritic cell-based immunotherapy.” Poster 162.

Gill J. “The challenge and costs in HIV of late presentations and disconnections from care.” Gilead Lunch Symposium.

Harris M, Hull M, Ochoa P, Toulson A, Montaner J. “Immediate vs. deferred substitution of dual boosted protese inhibitors (PIS) with darunavir/ritonavir (DRV/R).” Oral presentation.

Harris M, Hull M, Ochoa P, Toulson A, Montaner J. “Immediate vs. deferred substitution of dual boosted protease inhibitors (PIs) with darunavir/ritonavir (DRV/r).” Oral presentation.

Hogg R; Palmer AK, Milan D, Yip B, Klein M, Loutfy M, Raboud J, Machouf N, Rourke SB, Taylor D, Tsoukas C, Smieja M, Cooper C, Montaner J, CANOC Collaboration.“Canada’s National HIV Cohort Study: The Canadian Observational Cohort Collaboration (CANOC) (E).” Poster 226.

Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Cameron W, Sculpher M, Youle M, Anis AH, Owens DK. “Impact of treatment interruptions and mega-ART on health-related quality of life in the OPTIMA trial.” Canadian Journal of Infectious Diseases. Poster 134.

Kaida, A, Forrest J, Money D, Burdge D, Forbes J, Fernandes K, Milan D, Hogg R.“Antiretroviral adherence during pregnancy and postpartumamong HIV-positive women enrolled in the Drug Treatment Program in British Columbia, Canada.” Oral presentation.

Kamya PN, Boulet S, Cecile T, Bernard N, Investigators of the Montreal Slow Progressor Cohort. “Assessment of the functional potential of NK cells and NK cell subsets in HIV infected slow progressors carrying different KIR/HLA genotypes.” Oral presentation.

Keller M, Gill J, Tan D, Walmsley S, Lalonde RG, Klein M. “HIV-1 viral subtype affects CD4+ T-cell decline and clinical outcome in antiretroviral naïve patients receiving health care in Canada.” Oral presentation.

Loutfy, M, Genebat M, Moore DM, Chan K, Raboud J, Shen A, Li M, Klein M, Cooper C, Machouf N, Rourke SB, Tsoukas C, Smieja M, Montaner J, Hogg R, CANOC Collaboration. “Increased clinical events in HIV-infected patients who achieve full virologic suppression but fail to attain a CD4count ? 200 cells/mm3 after two years of combination antiretroviral therapy (cART).” Poster 208.

Machouf N, Ding E,. Lima VD, Palmer AK, Loutfy M, Klein M, Montaner J, Raboud J, Rachlis A, Smieja M, Tsoukas C, Cooper C, Rourke SB, Hogg R, CANOC Collaboration. “Time to virologic suppression among HIV-infected individuals on HAART in Canada (E).” Poster 209.

Mtambo A, Moore D, Chan K, Harrigan RP, Yip B, Montane J, Lima VD, Hogg R.“Treatment limitations imposed by antiretroviral drug resistance mutations: a comparison of initial regimenscontaining boosted PIs with those containing NNRTIs.” Oral presentation.

Moore D, Barrios R, Zhang W, Lepik KJ, Yip B, Shen A, Hogg R, Lima V, Bondi G, Montaner J. “Dyslipidemia associated with use of specific antiretroviral drugs in British Columbia, Canada.” Poster 160.

Raboud J, Bayoumi A, Su D, Loutfy M,Machouf N, Smieja M, Rachlis A, Tsoukas C, Smieja M, Rourke SB, Cooper C, Klein M, Montaner J, Hogg RS, CANOC Collaboration. “Regional differences in rates of viral load testing in Canada CANOC collaboration.” Poster 211.

Routy, JP. “HAART in action: Case discussions on current guidelines and beyond.” Bristol-Myers Squibb Lunch Symposium.

Routy JP, Vezina S, Tremblay C, Baril JG, Loutfy M; Gill J, Renu J, Nicolette C, Sekaly RP, Boulassel MR for the CTN 239 investigators. “Safety and feasibility of a multicentre phase II trial using autologous dendritic cell (DC) therapy to control viral replication following ART discontinuation (CTN 239).” Poster 163.

Singer J, Kyriakides T, Babiker A, Anis A, Brown S, Holodniy M, Angus B, Schechter MT, Cameron W. “Clinical outcomes from OPTIMA: A pragmatic randomised control trial of antiretroviral treatment strategies in advanced multi-drug resistant HIV infection.” Canadian Journal of Infectious Diseases. Oral presentation.

Singer J, Lapointe N, Money D, Alimenti A, Forbes J, Samson L, Bitnun A, Ayers D.“Perinatal HIV Transmission and maternal viral load: data from the Canadian Perinatal HIV Surveillance Program.” Oral presentation.

Singer J, Tremblay C, Rouleau D, Angel J, Trottier B, Montaner J, Baril JG, Trottier S, Bichel D, Routy JP. “RCT of valproic acid to purge HIV from resting CD4+ memory cells: Design, analysis and Study Progress.” Poster 144.

Singhal N, Su Y, Singer J, Cameron W. “The effect of mixed carotenoids supplementation on CD4 T lymphocyte count in HIV/AIDS.” Oral presentation.

Tan DH, Ota K, 2, Fisman D. “The impact of tenofovir-based HIV pre-exposure prophylaxison life expectancy and quality-adjusted life expectancy: A markov cohort model.” Oral presentation.

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, 19-22 July 2009

Anis A, Cameron DW, Sun H, Guh DP, Nosyk B, Bansback N, Singer J, Holodniy M, Brown ST, Kyriakides TC for the OPTIMA Study Group. “The effect of treatment on immune reconstitution of multi-drug resistant HIV/AIDS patients.” Poster.

Anis A, Barnett PG, Nosyk B, Chow A, Sun H, Sculpher MJ, Singer J. “A multinational comparison of the costs of treatment of late-stage HIV/AIDS in the OPTIMA Trial.” Poster.

Coutsinos D, Invernizzi CF, Moisi D, Oliveira M, Spira B, Xu H, Brenner BG, Wainberg MA. “Mechanisms of differential resistance development in subtype-B and C HIV-1: a study of the K65R, D67N, K103N, V106M and M184V drug resistance mutations.”

Durand M, Sheehy O, Baril jg, Lelorier J, Tremblay C, for the GRUCHUM (Groupe de Recherche de l’UHRESS du CHUM). “Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec’s public health insurance database (QPHID).” B39 Cardiovascular disease and other end organ damage.

Lisovsky I, Martinez Cajas JL, Oliveira M, Moisi D, Golubkov O, Wainberg MA.“Phenotypic Susceptibility and Drug Resistance Profile of HIV-1 B, C and AG Clones Selected with Atazanavir, Lopinavir and Nelfinavir.”

Routy JP. “Treatments to mobilize the reservoirs”. Determinants of viral reservoirs: Prospects for eradication. Oral presentation.

Routy JP, Jain R, Boulassel MR, Nicolette C, Finke L, Jacobson J. “Assessing risk of a 12-week antiretroviral therapy discontinuation as a read out of viral control in immune-based therapy (AGS-004-001 study).” Poster presentation.

Routy JP, Vezina S, Tremblay C, Angel J, Baril JG, Loufty M, Gill J, Jain R, Nicolette C, Sekaly R, Boulassel MR, and the, Canadian HIV Trials network CIHR/CTN 239 investigators. “Safety and feasibility of a multicentre phase 2 trial using autologous dendritic cell (DC) therapy to control viral replication following ART discontinuation.” B42.

Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, Brenner B, Roger M, Shafer R, Cantin R, Zolopa A. “Genotypic, phenotypic and virtual phenotypic resistance patterns for tipranavir (TPV) and darunavir (DRV): An independent analysis of a Quebec HIV-1 cohort highly resistant to all other protease inhibitors.”

Wainberg MA, Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG.“Mechanistic Analysis of the Preference for the K65R Multi-Resistance Nucleoside Mutation in Subtype C Viruses.”

Research Publications 2008

Articles on CTN studies

January 1, 2008 – December 31, 2008

Bansback N, Sun H, Guh DP, Li X, Nosyk B, Griffin S, Barnett PG, Anis AH; OPTIMA TEAM. “Impact of the recall period on measuring health utilities for acute events.” Health Econ. 2008 Apr 10; [Epub ahead of print].

Burman W, Grund B, Neuhaus J, Douglas J Jr, Friendland G, Telzak E, Colebunders R, Paton N, Fisher M, Rietmeijer C for the SMART study group and INSIGHT. “Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy:  results of a randomized controlled trial.” J Acquir Immun eDefic Synd 2008;49: 142-150.

Burman W, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW for the SMART study group. “The impact of episodic CD4 cell count-guided antiretroviral therapy on quality of life.” J Acquir Immun eDefic Synd 2008; 47(2): 185-193.

Carr A, Grund B,Neuhaus J, El-Sadr WM, Grandits G, Gibert C, Prineas RJ for the SMART Study Investigators. “Asymptomatic mycocardial ischaemia in HIV-infected adults.” AIDS 2008; 22(2): 257-267.

Cooper C, Mills E, Wabwire BO, Ford N, Olupot-Olupot P. “Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa.” Int J Infect Dis.2008 Nov 10.

Holodniy M. “The OPTIMA Trial”. In:  A Decade of HAART. Zuniga JM, Bartlett JG, Whiteside S, Lange MA, Eds Oxford Press 2008

Klein MB, Cooper C, Brouillette MJ, Sheehan NL, Benkelfat C, Annable L, Weston F, Kraus D, Singer J; for the CTN194 Investigators. “CTN-194 (PICCO):  Design of a trial of citalopram for the prevention of depression and its consequences in HIV-Hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.” ContemPClin Trials. Epub 2008 Jan 12.

SMART study group. “Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study:  role of CD4+ cell counts and HIV RNA levels during follow-up.” J Infect Dis 2008; 197: 1145-1155.

SMART study group. “Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy, a randomized trial.” Ann Intern Med 2008; 149: 289-299.

SMART study group. “Major clinical outcomes in antiretroviral therapy (ART)-naïve participants and in those not receiving ART at baseline in the SMART study.” J Infect Dis2008; 197: 1133-1144.

SMART/INSIGHT and D: A: D study groups. “Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infraction in HIV-infected patients.” AIDS 2008;22: F17-F24.

Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, Klein MB, Dore GJ, Mocroft A, Soriano V, Clotet B, Lundgren JD for the SMART study group and international network for strategic initiatives in global HIV trials (insight). “Opportunistic disease and mortality in patients coinfected with hepitatis B or C virus in the strategic management of antiretroviral therapy (SMART) study.” Clin Infect Dis 2008; 47:  1468-1475.

van Grevenynghe J, Procopio FA, He Z, Chomont N,Riou C, Zhang Y , Gimmig S, Boucher G , Wilkinson P, Shi Y, Yassine-Diab B, Said EA, Trautmann L, El Far M, Balderas RS, Boulassel MR, Routy JP, Haddad EK, Sekaly RP. “Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection.” Nat Med . Epub 2008 Mar 2.

Wendler D, Krohmal B, Emanuel EJ, Grady C for the ESPRIT group. “Why patients continue to participate in clinical research.” Arch Intern Med 2008; 168(12):  1294-1299.

Wood E, Montaner J. “Antiretroviral therapy:  a key part of the public health response to injection drug use.” Addiction. 2008 Apr;103(4): 660-1. No abstract available. [PubMed – in process].

Wood E, Montaner J, Li K, Zhang R, Barney L, Strathdee SA, Tyndall MW, Kerr T.“Burden of HIV infection among aboriginal injection drug users in Vancouver, British Columbia.” Am J Public Health. 2008 Mar; 98(3): 515-9. Epub 2008 Jan 30.

Articles by CTN Investigators

January 1, 2008 – December 31, 2008

Alvarez G. “Deviations from Hardy-Weinberg proportions for multiple alleles under viability selection.” Genet Res. 2008 Apr; 90(2): 209-16.

Azizi N, Brazete J, Hankins C, Money D, Fontaine J, Koushik A, Rachlis A, Pourreaux K, Ferenczy A, Franco E, Coutlée F for The Canadian Women’s HIV Study Group.“Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia.” J Gen Virol. 2008 Jul;89 (Pt 7): 1716-28.

Bestawros A, Boulassel MR, Michel RP, Routy JP. “HHV-8 linked to Kaposi’s sarcoma, Castleman’s disease and primary effusion lymphoma in a HIV-1-infected man.” J Clin Virol. 2008 Mar 13; [Epub ahead of print].

Boulet S, Sharafi S, Simic N, Bruneau J, Routy JP, Tsoukas CM, Bernard NF.“Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals.”AIDS. 2008 Mar 12; 22(5): 595-9.

Brenner BG, Roger M, Moisi D., Oliveira M, Hardy I, Turgel R, Charest H, Routy JP, Wainberg MA, and the Montreal PHI Cohort and HIV Prevention Study Groups.“Transmission networks of drug resistance acquired in primary/early stage HIV infection”.AIDS 2008 November 30; Volume 22(18) 2509-2515.

Burgoyne RW, Tan D. “Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART):  a balancing act.” J Antimicrob Chemother. 2008 Jan 3.

Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, Gilmore N, King MS, Bernstein BM, Brun SC, Hanna GJ. “A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.” J Infect Dis. 2008 Jul 15; 198(2): 234-240.

Cooper C. “An overview of HIV and chronic Viral hepatitis co-infection.” Dig Dis Sci. 2008 Apr; 53(4):  899-904.

Cooper C, Ahluwalia NK, Efler SM, Vollmer J, Krieg AM, Davis HL. “Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers.” J Immune Based Ther Vaccines. 2008 Jun 9; 6: 3.

Costiniuk CT, Camacho F, Cooper C. “Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.” Clin Infect Dis. 2008 Jul 15;47(2): 198-202.

Costiniuk CT, Mills E, Cooper C. “Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.” Can J Gastroenterol. 2008 Apr; 22(4): 376-80.

Fontaine J, Hankins C, Money D, Rachlis A, Pourreaux K, Ferenczy A; Canadian Women’s HIV Study Group, Coutlée F. “Human papillomavirus type 16 (HPV-16) viral load and persistence of HPV-16 infection in women infected or at risk for HIV.” J Clin Virol.2008 Nov; 43(3): 307-12. Epub 2008 SeP10.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Huppler Hullsiek K, Stephan C, Lundgren J on behalf of the SMART study group. “Viral resuppression and detection of drug assistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.” AIDS 2008; 22: 2279-2289.

Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MA, Veazey RS, Wainberg MA. “Whither or Wither microbicides?” Science. 2008; 321:  532-534. 

Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, Kalousek K, Duncan F, Tyndall MW, Fraser C, Conway B, Fischer B. “Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.” Drug Alcohol Depend. 2008 Jan 11;93(1-2): 141-147. Epub 2007 Nov 9.

Gutiérrez S, Guillemi S, Jahnke N, Montessori V, Harrigan PR, Montaner J. “Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.” Clin Infect Dis. 2008 Feb 1;46(3): e28-30.

Huang KH, Loutfy MR, Tsoukas CM, Bernard NF. “Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption.” BMC Infect Dis. 2008 May 2;8: 59.

Hull MW, Phillips P, Montaner J. “Changing global epidemiology of pulmonary manifestations of HIV/AIDS.” Chest. 2008 Dec; 134(6): 1287-98.

Joy R, Druyts EF, Brandson EK, Lima VD, Rustad CA, Zhang W, Wood E, Montaner J, Hogg R. “Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting.” J Acquir Immune Defic Syndr. 2008 Jan 11.

Keller M, Mak A, Thibert L, Rene P, Klein MB. “Mycobacterium haemophilum epididymal abscess in a renal transplant patient.” J Clin Microbiol. 2008 Jul; 46(7): 2459-60. Epub 2008 May 28.

Keynan Y, Card CM, McLaren PJ, Dawood MR, Kasper K, Fowke KR. “The role of regulatory T cells in chronic and acute viral infections.” Clin Infect Dis. 2008 Apr 1; 46(7): 1046-52.

Kiboneka A, Wangisi J, Nabiryo C, Tembe J, Kusemererwa S, Olupot-Olupot P, Joffres M, Anema A, Cooper C, Montaner J, Mills EJ. “Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda.”AIDS. 2008 Nov 30; 22(18): 2493-9.

Kowal J, Overduin LY, Balfour L, Tasca GA, Corace K, Cameron DW. “The Role of Psychological and Behavioral Variables in Quality of Life and the Experience of Bodily Pain Among Persons Living with HIV.” J Pain Symptom Manage. 2008 Apr 12; [Epub ahead of print].

Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD for the INSIGHT study group. “Inflammatory and coagulation biomakers and mortality in patients with HIV infection.”PLoS Med 2008; 5(10):  e203.doi:  10.1371/journal.pmed.005.

Lifson AR, and the INSIGHT Cause of Death Writing Group:  Belloso WH, Carey C, Davey RT, Duprez D, El-Sadr WM, Gaatell JM, Gey DC, Hoy JF, Krum EA, Nelson R, Nixon DE, Paton N, Pedersen C, Perez G, Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J. “Determination of the underlying cause of death in three multicenter international HIV clinical trials.” HIV Clin Trials 2008; 9:  177-185.

Liu L, May S, Richman DD, Hecht FM, Markowitz M, Daar ES, Routy JP, Margolick JB, Collier AC, Woelk CH, Little SJ, Smith DM. “Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance.” AIDS. 2008 Apr 23;22(7): 835-9.

Loutfy MR, Macdonald S, Myhr T, Husson H, Du Mont J, Balla S, Antoniou T, Rachlis A.“Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors.”Antivir Ther. 2008;13(1): 87-95.

Low AJ, Marchant D, Brumme CJ, Brumme ZL, Dong W, Sing T, Hogg R, Montaner J, Gill V, Cheung PK, Harrigan PR. “CD4-dependent characteristics of coreceptor Use and HIV type 1 V3 sequence in a large population of therapy-naïve individuals.” AIDS Res Hum Retroviruses. 2008 Feb; 24 (2): 219-28.

Martinez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. “Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance:  a systematic review of virologic and biochemical evidence.” AIDS Rev. 2008 Oct-Dec; 10(4): 212-23.

Martinez-Cajas JL, Wainberg MA. “Antiretroviral therapy:  optimal sequencing of therapy to avoid resistance.” Drugs. 2008; 68(1): 43-72

Mishra S, Walmsley SL, Loutfy MR, Kaul R, Logue KJ, Gold WL. “Otosyphilis in HIV-coinfected individuals:  a case series from Toronto, Canada.” AIDS Patient Care STDS. 2008 Mar; 22(3): 213-9.

Newman PA, Daley A, Halpenny R, Loutfy M. “Community heroes or “high-risk” pariahs? Reasons for declining to enroll in an HIV vaccine trial.” Vaccine. 2008 Feb 20; 26(8):  1091-7. Epub 2008 Jan 3.

Ntemgwa M, Gill MJ, Brenner BG, Moisi D, Wainberg MA. “Discrepancies in assignment of subtype/recombinant forms by genotyping programs for HIV type 1 drug resistance testing may falsely predict superinfection.” AIDS Res Hum Retroviruses. 2008 Jul 1.

Ntemgwa M, Toni TD, Brenner BG, Routy JP, Moisi D, Oliveira M, Wainberg MA. “Near full-length genomic analysis of a novel subtype A1/C recombinant HIV type 1 isolate from Canada.” AIDS Res Hum Retroviruses. 2008 Apr;24(4): 655-9.

Pant Pai N, Barick R, Tulsky JP, Shivkumar PV, Cohan D, Kalantri S, Pai M, Klein MB, Chhabra S. “Impact of round-the-clock, rapid oral fluid HIV testing of women in labor in rural India.” PLoS Medicine. 2008 5 [5]:  e92.

Phillips E, Hayden A, Gutiérrez S, Jahnke N, YiPB, Lima VD, Hogg R, Harrigan PR, Montaner J. “Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity:  authors’ reply.”AIDS. 2008 Feb 19;22(4): 548-9. No abstract available.

Raffa JD, Tossonian HK, Grebely J, Petkau AJ, DeVlaming S, Conway B. “Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations.” J Acquir Immune Defic Syndr. 2008 Mar 1;47(3): 397-9.

Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D; VASST Investigators. “Vasopressin versus norepinephrine infusion in patients with septic shock.” N Engl J Med. 2008 Feb 28;358(9):877-87.

Shepard BD, Loutfy MR, Raboud J, Mandy F, Kovacs CM, Diong C, Bergeron M, Govan V, Rizza SA, Angel JB, Badley AD. “Early changes in T-cell activation predict antiretroviral success in salvage therapy of HIV infection.” J Acquir Immune Defic Syndr. 2008 Mar 20; [Epub ahead of print].

Sylla M, Chamberland A, Boileau C, Traoré HA, Ag-Aboubacrine S, Cissé M, Koala S, Drabo J, Diallo I, Niamba P, Tremblay-Sher D, Machouf N, Rashed S, Nickle DC, Nguyen VK, Tremblay CL; ATARAO Group. “Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso.” Antivir Ther. 2008;13(1): 141-8.

Tan DH, Sigler L, Gibas CF, Fong IW. “Disseminated fungal infection in a renal transplant recipient involving macrophomina phaseolina and scytalidium dimidiatum:  case report and review of taxonomic changes among medically important members of the botryosphaeriaceae.” Med Mycol . 2008 May;46(3): 285-92

Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V. “Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.” AIDS. 2008 Jan 11;22(2): 275-9.

Walmsley SL, Katlama C, Lazzarin A, Arestéh K, Pierone G, Blick G, Johnson M, Meier U, MacGregor TR, Leith JG. “Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51).” J Acquir Immune Defic Syndr. 2008 Apr 1; 47(4):  429-40.

Wilson DP, Coplan PM, Wainberg MA, Blower SM. “The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics.” Proc Natl Acad Sci USA. 2008 Jul 15;105(28): 9835-40. Epub 2008 Jul 7.

Worthington CA, Gill MJ. “Participation in HIV research:  the importance of clinic contact factors.” AIDS Patient Care STDS . 2008 Jul 15. [Epub ahead of print]

Yue FY, Merchant A, Kovacs CM, Loutfy M, Persad D, Ostrowski MA. “Viral specific IL-17 producing CD4+ T cells are detectable in early HIV-1 infection.” J Virol. 2008 Apr 23; [Epub ahead of print].

Latest News

Why do we need PrEP Guidelines? Ask an expert. VIDEO

| Uncategorized | No Comments

Despite efforts to reduce new incidences of HIV like condom campaigns, needle exchanges, and treatment as prevention, the actual number…

Call for Nominations: Community Advisory Committee (CAC) 2018

| Uncategorized | No Comments

The CIHR Canadian HIV Trials Network (CTN/Network) is an innovative partnership funded by the Canadian Institutes of Health Research to…

Guest Blog: Dr. Nadine Kronfli on HCV treatment in Canadian prisons

| Hepatitis C | No Comments

Persons in custody in Canadian prisons have a 25-fold higher rate of hepatitis C (HCV) infection than the general population….

Guest Blog: CTN Postdoc Dr. Malika Sharma

| Uncategorized | No Comments

CTN Postdoctoral Fellow Dr. Malika Sharma writes about the current state of PrEP in Canada and how CTN 303 looks to change the way these HIV prevention drugs are delivered.